<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Rituximab for thyroid‐associated ophthalmopathy - Kang, S - 2022 | Cochrane Library</title> <meta content="Rituximab for thyroid‐associated ophthalmopathy - Kang, S - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009226.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Rituximab for thyroid‐associated ophthalmopathy - Kang, S - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009226.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009226.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Rituximab for thyroid‐associated ophthalmopathy" name="citation_title"/> <meta content="Swan Kang" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="swan.kang1@nhs.net" name="citation_author_email"/> <meta content="Shirin Hamed Azzam" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Neda Minakaran" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Daniel G Ezra" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009226.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/06/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009226.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009226.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009226.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [therapeutic use]; Diplopia [drug therapy]; *Graves Ophthalmopathy [drug therapy]; Mice; Rituximab [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009226.pub3&amp;doi=10.1002/14651858.CD009226.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009226\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009226\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","hr","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009226.pub3",title:"Rituximab for thyroid\\u2010associated ophthalmopathy",firstPublishedDate:"Jun 16, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009226.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009226.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009226.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009226.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009226.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009226.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009226.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009226.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009226.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009226.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2518 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009226.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0080"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-sec-0074"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/appendices#CD009226-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/references#dataAndAnalyses"> Analyses </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Rituximab for thyroid‐associated ophthalmopathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#CD009226-cr-0004">Swan Kang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#CD009226-cr-0005">Shirin Hamed Azzam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#CD009226-cr-0006">Neda Minakaran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information#CD009226-cr-0007">Daniel G Ezra</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information/en#CD009226-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 June 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009226.pub3">https://doi.org/10.1002/14651858.CD009226.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009226-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009226-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009226-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009226-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009226-abs-0007">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009226-abs-0001" lang="en"> <section id="CD009226-sec-0001"> <h3 class="title" id="CD009226-sec-0001">Background</h3> <p>Thyroid‐associated ophthalmopathy (TAO) is the most frequent extrathyroidal manifestation of Graves' disease, affecting up to 50% of patients. It has a great impact on quality of life. Rituximab (RTX) is a human/murine chimeric monoclonal antibody that targets the CD20 receptor on B‐lymphocytes. Preliminary work has shown that blocking this CD20 receptor with RTX may affect the clinical course of TAO by reducing inflammation and the degree of proptosis.  </p> </section> <section id="CD009226-sec-0002"> <h3 class="title" id="CD009226-sec-0002">Objectives</h3> <p>This review update, originally published in 2013, assesses the efficacy and safety of using RTX for the treatment of TAO. </p> </section> <section id="CD009226-sec-0003"> <h3 class="title" id="CD009226-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 2), which contains the Cochrane Eyes and Vision Trials Register, Ovid MEDLINE, Ovid Embase, Latin American and Caribbean Health Science Information database (LILACS), the ISRCTN registry, clinicaltrials.gov and the WHO International Clinical Trials Registry Platform (WHO ICTRP). There were no language restrictions in the electronic search for trials. We last searched the electronic databases on 22 February 2022.  </p> </section> <section id="CD009226-sec-0004"> <h3 class="title" id="CD009226-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of RTX administered by intravenous infusion using any dosage regimen for the treatment of active TAO in adults, compared to placebo or glucocorticoids treatment.  </p> </section> <section id="CD009226-sec-0005"> <h3 class="title" id="CD009226-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Two review authors independently scanned titles and abstracts, and screened full‐text reports of potentially relevant studies. The outcomes of interest in this review were: clinical activity score (CAS), NOSPECS severity scale, proptosis (mm), palpebral aperture (mm), extraocular motility (degrees or diplopia rating scale), quality of life and adverse effects. </p> </section> <section id="CD009226-sec-0006"> <h3 class="title" id="CD009226-sec-0006">Main results</h3> <p>We identified two studies that met the inclusion criteria in this updated review. Across both studies, the mean age of participants was 55 years and 77% were women. </p> <p><i>RTX compared to intravenous methylprednisolone (IVMP)</i> </p> <p>One study, conducted in Italy, compared RTX (n = 15 after one participant withdrew) with IVMP (n = 16) for active TAO (CAS ≥ 3 out of 7 or 4 out of 10). We judged this study to be at low risk of bias in most domains, but it was stopped early because of disease reactivation in the comparator group (5/16 participants). This study provided low‐certainty evidence that RTX may result in CAS improvement at 24 weeks compared to IVMP (15/15 versus 12/16 improved by ≥ 2 points; risk ratio (RR) 1.32, 95% confidence interval (CI) 0.98 to 1.78). Only very low‐certainty evidence was available for the other outcomes: NOSPECS improvement by 2 or more classes (3/15 versus 3/16; RR 1.07, 95% CI 0.25 to 4.49); proptosis improvement by 2 mm or more (0/15 versus 1/16; RR 0.35, 95% CI 0.02 to 8.08); palpebral aperture improvement by 3 mm or more (2/15 versus 0/16; RR 5.31, 95% CI 0.28 to 102.38); motility improvement by 1 class or more (3/15 versus 3/16; RR 1.07, 95% CI 0.25 to 4.49); and improvement on the Graves’ ophthalmopathy QoL scale by at least 6 points for "functioning" (5/14 versus 8/13; RR 0.58, 95% CI 0.25 to 1.32), and “appearance” (9/14 versus 6/13; RR 1.39, 95% CI 0.69 to 2.82). Adverse events were more common in the RTX group (RR 1.39, 95% CI 0.90 to 2.13; low‐certainty evidence). Minor adverse effects (mild infusion reactions) were observed in most people receiving RTX at first infusion. Two participants experienced a major infusion reaction, likely cytokine release syndrome. </p> <p><i>RTX compared to placebo</i> </p> <p>One study, conducted in the USA, enrolled 25 participants with active TAO (CAS ≥ 4 out of 7), comparing RTX (13 participants) to placebo. We judged this study to be at low risk of bias in most domains, but it was stopped early due to recruitment issues. It provided very low‐certainty evidence on the following outcomes at 24 weeks: CAS improvement by 2 or more points (4/13 RTX versus 3/12 placebo; RR 1.23, 95% CI 0.34 to 4.40); NOSPECS improvement by 2 or more classes (2/13 versus 2/12; RR 0.92, 95% CI 0.15 to 5.56); proptosis improvement by 2 mm or more (2/13 versus 4/12; RR 0.46, 95% CI 0.10 to 2.08); palpebral aperture median change (0 mm in RTX group, in both eyes separately, versus ‐0.5 mm and 0.5 mm in placebo group right and left eye, respectively); motility median diplopia score (3 versus 2.5); SF‐12 physical component median score (45.9 versus 40.3) and mental component median score (52.8 versus 46.1). More participants in the RTX group experienced adverse effects (8/13 versus 3/12; RR 2.46, 95% CI 0.84 to 7.18).  </p> </section> <section id="CD009226-sec-0007"> <h3 class="title" id="CD009226-sec-0007">Authors' conclusions</h3> <p>There is currently insufficient evidence to support the use of RTX in people with TAO. Future studies investigating RTX in people with active TAO may need to be multi‐centre in order to recruit enough participants to make an adequate judgement on the efficacy and safety of this novel therapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009226-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009226-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009226-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009226-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009226-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009226-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009226-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009226-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009226-abs-0002" lang="en"> <h3>What are the benefits and risks of rituximab (a medicine that reduces inflammation) for the treatment of thyroid‐associated ophthalmopathy (a disease affecting the tissues surrounding the eyes) </h3> <p><b>Key messages</b><br/>‐ We did not find enough evidence to show that people with moderate to severe thyroid‐associated ophthalmopathy who have treatment with rituximab have any different outcome in terms of signs and symptoms of disease compared to those treated with steroid or placebo (dummy treatment).  </p> <p>‐ Rituximab may cause more adverse (unwanted) effects compared to steroids or a placebo, but we are not certain of this. </p> <p>‐ More studies are needed to strengthen the body of evidence and investigate whether rituximab should be used for the treatment of thyroid‐associated ophthalmopathy. </p> <p><b>What is thyroid‐associated ophthalmopathy?</b><br/>Thyroid‐associated ophthalmopathy is an eye disease that affects half of people that have Graves' disease, a condition where the body's immune system attacks the thyroid gland and makes it overactive. In thyroid‐associated ophthalmopathy the body's immune system also attacks the tissues surrounding the eyes. Symptoms include eye pain, redness, swelling, eye protrusion (proptosis), double vision, and in severe cases, reduction in vision.  </p> <p><b>How is thyroid‐associated ophthalmopathy treated?</b><br/>Treatment options for severe thyroid‐associated ophthalmopathy include anti‐inflammation medicines called steroids, and radiotherapy.  However, relapses are common. Surgery to relieve the pressure that builds up behind the eye (orbital decompression) is usually reserved for sight‐threatening cases.  </p> <p>A possible alternative treatment is a medicine called rituximab, given as an intravenous infusion (injection into the vein), which aims to stop the body’s defence system (immune system) from mistakenly attacking its healthy tissues and causing inflammation. </p> <p><b>What did we want to find out?</b><br/>We wanted to compare the benefits and risks of rituximab against those of other treatments for thyroid‐associated ophthalmopathy. </p> <p><b>What did we do?</b><br/>We searched for studies that compared rituximab against placebo (dummy) treatment or steroid treatment for thyroid‐associated ophthalmopathy. We compared and summarised the results of these studies and rated our confidence in the evidence, based on factors such as study methods and sizes of participant groups. </p> <p><b>What did we find?</b><br/>We found two studies, conducted in Italy and the USA, involving a total of 56 people with thyroid‐associated ophthalmopathy. Everyone taking part in the study was aged 18 to 80 years (average age 55 years) and 77% were women. One study (31 people) compared intravenous rituximab (2 x 1000 mg infusions given 2 weeks apart or a single infusion of 500 mg) to intravenous methylprednisolone (steroid). The other study (25 people) compared intravenous rituximab (2 x 1000 mg infusions given 2 weeks apart) to intravenous placebo (dummy) infusions. As the studies compared rituximab to different alternative treatments, it was not possible to combine the studies' results to analyse them together. </p> <p><b>What were the main results of our review?</b><br/>The evidence suggests that rituximab, compared to intravenous methylprednisolone, may result in an improvement in how 'active' the thyroid‐associated ophthalmopathy is at 24 weeks following treatment when measured using one particular scale, but the evidence for whether there was a true difference was uncertain. Furthermore, there was little to no difference when thyroid‐associated ophthalmopathy activity was measured using a different scale. There was no evidence of a difference in the following outcomes, measured at 24 weeks following treatment: </p> <p>‐ reduction in eye protrusion </p> <p>‐ reduction in how wide open the eyelids are</p> <p>‐ improvement in eye movement and double vision</p> <p>‐ improvement in quality of life</p> <p>The evidence suggests that rituximab, compared to placebo, results in little to no difference in any of the outcomes outlined above, measured at 24 weeks following treatment. </p> <p>The number of adverse events was higher for rituximab compared to both intravenous methylprednisolone and placebo, but the evidence for whether there was a true difference was uncertain. </p> <p><b>What are the limitations of the evidence?</b><br/>The evidence is only based on two studies with few participants, and both of these studies were stopped earlier than originally planned, which limits our confidence in the findings.  </p> <p><b>How up‐to‐date is the evidence?</b><br/>The evidence is current to February 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009226-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009226-sec-0080"></div> <h3 class="title" id="CD009226-sec-0081">Implications for practice</h3> <section id="CD009226-sec-0081"> <p>Currently, available literature suggests contradictory evidence on the efficacy of rituximab therapy for active thyroid‐associated ophthalmopathy (TAO). Important differences in the trial protocols and study population prevented meaningful collation and analysis of data. Rituximab (RTX) therapy appears to be associated with frequent, mostly mild side effects. However, severe adverse reactions such as dysthyroid optic neuropathy and cytokine release syndrome should be anticipated and managed at experienced centres. No evidence‐based recommendation regarding the use of rituximab for TAO can be made at present. </p> </section> <h3 class="title" id="CD009226-sec-0082">Implications for research</h3> <section id="CD009226-sec-0082"> <p>Larger multi‐centre randomised controlled double‐masked trials are still needed to provide the data that can be utilised to make an adequate judgement on the efficacy and safety of this novel therapy in TAO. These trials should be designed to include people with moderate to severe TAO (clinical activity score (CAS) ≥ 4) who have been euthyroid for at least six weeks. Both treatment‐naïve people and people who have relapsed following previous glucocorticoid therapy could be investigated, as in the two trials included in this review. Participants should be randomised to receive intravenous rituximab or to receive intravenous glucocorticoids or intravenous saline/placebo. The primary outcome could be change in two or more of the following outcomes without deterioration in any outcome in either eye, as proposed by the European Group on Graves' Orbitopathy (EUGOGO) (<a href="./references#CD009226-bbs2-0017" title="BartalenaL , KrassasGE , WiersingaW , MarcocciC , SalviM , DaumerieC , et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2012;97(12):4454-63.">Bartalena 2012</a>). </p> <p> <ol id="CD009226-list-0007"> <li> <p>Improvement in the palpebral aperture by 3 mm</p> </li> <li> <p>Improvement in NOSPECS* class II signs by 2 grades</p> </li> <li> <p>Improvement in Bahn–Gorman diplopia score or improvement of 8° in motility</p> </li> <li> <p>Improvement in proptosis by 2 mm</p> </li> <li> <p>Improvement in CAS by 2 or more points)</p> </li> </ol> </p> <p>*The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C. </p> <p>Participants should be followed up long‐term and relapse rates recorded. Improvement in quality of life is also an important outcome that future studies should investigate, measured using validated tools such as the SF‐36 health questionnaire (<a href="./references#CD009226-bbs2-0072" title="Ware JE Jr, GandekB . Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology1998;51(11):903-12.">Ware 1998</a>) and Grave's Ophthalmopathy Quality of Life questionnaire (GO‐QoL) (<a href="./references#CD009226-bbs2-0066" title="TerweeCB , DekkerFW , MouritsMP , GerdingMN , BaldeschiL , KalmannR , et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clinical Endocrinology2001;54(3):391-8.">Terwee 2001</a>). Adverse effects and side‐effect profiles should be recorded, including longer‐term follow‐up such as 24 months post‐treatment.  </p> <p>This is an exciting area of development, and as more research is conducted to understand further the pathophysiology of TAO and particularly its immune basis, more immune‐modulating agents can be developed and trialled to take us one step further in managing this serious and potentially sight‐threatening condition. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009226-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009226-sec-0008"></div> <div class="table" id="CD009226-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> thyroid‐associated ophthalmopathy<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> rituximab<br/><b>Comparison:</b> intravenous methylprednisolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravenous methylprednisolone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rituximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAS improvement (decrease) by 2 or more points<br/>follow‐up: 24 weeks<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>990 per 1000</b><br/>(735 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b><br/>(0.98 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NOSPECS improvement (decrease) by 2 or more classes<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(47 to 842) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.25 to 4.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proptosis improvement (decrease) by 2 mm or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(1 to 505) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.35</b><br/>(0.02 to 8.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Palpebral aperture improvement (decrease) by 3 mm or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.31</b><br/>(0.28 to 102.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><br/>(3 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motility improvement (increase) by 1 class or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(47 to 842) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.25 to 4.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life improvement by at least 6 points<br/>assessed with: GO‐QoL<br/>follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Improvement on GO‐QoL Scale by at least 6 points for "functioning": RR at 24 weeks 0.58 (95% CI 0.25 to 1.32)Improvement on GO‐QoL Scale by at least 6 points for "appearance": RR at 24 weeks 1.39 (95% CI 0.69 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>869 per 1000</b><br/>(563 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.39</b><br/>(0.90 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the rituximab group, 2 participants experienced a major infusion reaction, likely cytokine release syndrome. Minor adverse effects (mild infusion reactions) were observed in most rituximab patients at first infusion. In IVMP group, 3 participants experienced deranged liver function test. Minor side effects observed in 7 IVMP participants were dyspepsia, hypotension, insomnia, and mild mood disorders, which did not require specific treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424436778554984307" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424436778554984307</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> CAS: clinical activity score; GO‐QoL: Graves’ ophthalmopathy quality of life questionnaire; NOSPECS: scoring system based on no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement, and sight loss; RCT: randomised clinical trial; SF‐12: Medical Outcomes Study 12‐Item Short Form Health Survey.<br/><sup>b</sup> Downgraded one level for serious risk of bias: study was stopped early. <br/><sup>c</sup> Downgraded one level for imprecision: small study, wide confidence intervals including no effect<br/><sup>d</sup> Downgraded two levels for imprecision: small study with few events, very wide confidence intervals<br/><sup>e</sup> Downgraded one level for inconsistency: effects on quality of life are inconsistent </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009226-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Rituximab compared to placebo for thyroid‐associated ophthalmopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rituximab compared to placebo for thyroid‐associated ophthalmopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> thyroid‐associated ophthalmopathy<br/><b>Setting:</b> Hospital<br/><b>Intervention:</b> Rituximab<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Rituximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAS improvement (decrease) by 2 or more points<br/>follow‐up: 24 weeks<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/>(85 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b><br/>(0.34 to 4.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NOSPECS improvement (decrease) by 2 classes or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b><br/>(25 to 927) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.15 to 5.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proptosis improvement (decrease) by 2 mm or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b><br/>(33 to 693) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b><br/>(0.10 to 2.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpebral aperture change<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median change in palpebral aperture in the right eye was 0 mm (IQR ‐1 to 1) in the 13 rituximab group participants and ‐0.5 mm (IQR ‐1 to 1.75) in the 12 placebo participants. Median change in the palpebral aperture in the left eye was 0 mm (IQR ‐1.5 to 1) in the rituximab group and 0.5 mm (IQR ‐1 to 1.75) in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motility<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The median diplopia score in the 13 rituximab participants was 3 (IQR 2 to 3.5) compared to 2.5 (IQR 0 to 4) in the 12 placebo participants. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life<br/>assessed with: SF‐12 physical and mental<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>SF‐12 physical: the median score was 45.9 (IQR 43.6 to 50.8) in the 13 rituximab participants and 40.3 (IQR 38.5 to 52.1) in the 12 placebo participants. SF‐12 mental: the median score was 52.8 (IQR 36.1 to 56.7) in the rituximab group and 46.1 (IQR 35.4 to 57.4) in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>615 per 1000</b><br/>(210 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.46</b><br/>(0.84 to 7.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were four adverse events in 3 out of 12 placebo patients (1 moderate/severe) and 11 adverse events in 8 out of 13 rituximab‐treated patients (5 moderate/severe). Moderate/severe adverse effects included infections (bronchitis, conjunctivitis), vasculitis, optic neuropathy and gastrointestinal adverse effects including tongue pain, abdominal pain and diarrhoea. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424437036185390139" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424437036185390139</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> CAS: clinical activity score; IQR: interquartile range; GO‐QoL: Graves’ ophthalmopathy quality of life questionnaire; NOSPECS: scoring system based on no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement, and sight loss; RCT: randomised clinical trial; SF‐12: Medical Outcomes Study 12‐Item Short Form Health Survey.<br/><sup>b</sup> Downgraded one level for serious risk of bias: study was stopped early<br/><sup>c</sup> Downgraded two levels for imprecision: small study and (where confidence intervals could be calculated) very wide confidence intervals including no effect<br/><sup>d</sup> Downgraded one level for inconsistency: different findings in right and left eye </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009226-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009226-sec-0009"></div> <section id="CD009226-sec-0010"> <h3 class="title" id="CD009226-sec-0010">Description of the condition</h3> <p>Thyroid‐associated ophthalmopathy (TAO) is the most frequent extrathyroidal manifestation of Graves' disease, an autoimmune thyroid disorder that also affects the connective tissue of the orbit and skin. Graves' disease affects approximately 1% to 2% of the adult population (<a href="./references#CD009226-bbs2-0073" title="WeetmanAP . Graves' disease. New England Journal of Medicine2000;343(17):1236-48.">Weetman 2000</a>), and approximately 20% to 25% of people with Graves' hyperthyroidism have clinically apparent TAO at the time of diagnosis (<a href="./references#CD009226-bbs2-0022" title="BurchHB , WartofskyL . Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Reviews1993;14(6):747-93.">Burch 1993</a>, <a href="./references#CD009226-bbs2-0065" title="TandaML , PiantanidaE , LiparuloL , VeronesiG , LaiA , SassiL , et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. Journal of Clinical Endocrinology and Metabolism 2013;98(4):1443-9.">Tanda 2013</a>). In total, TAO affects up to 50% of these patients clinically (<a href="./references#CD009226-bbs2-0074" title="WiersingaWM , BartalenaL . Epidemiology and prevention of Graves' ophthalmopathy. Thyroid2002;12(10):855-60.">Wiersinga 2002</a>), and in 70%, magnetic resonance imaging (MRI) or computed tomographic (CT) scanning reveals extraocular muscle enlargement (<a href="./references#CD009226-bbs2-0028" title="EnzmannDR , DonaldsonSS , KrissJP . Appearance of Graves' disease on orbital computed tomography. Journal of Computer Assisted Tomography1979;3(6):815-9.">Enzmann 1979</a>; <a href="./references#CD009226-bbs2-0069" title="VilladolidMC , YokoyamaN , IzumiM , NishikawaT , KimuraH , AshizawaK , et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. Journal of Clinical Endocrinology and Metabolism1995;80(9):2830-3.">Villadolid 1995</a>). It may also occur in people with euthyroid or hypothyroid chronic autoimmune thyroiditis (<a href="./references#CD009226-bbs2-0016" title="BartalenaL , BaldeschiL , DickinsonAJ , EcksteinA , Kendall-TaylorP , MarocciC , et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid2008;18(3):333-46.">Bartalena 2008</a>).  </p> <p>TAO is characterised by inflammation of the orbital connective tissue, inflammation and fibrosis of the extraocular muscles, and adipogenesis within the orbits (<a href="./references#CD009226-bbs2-0014" title="BahnRS . Graves' ophthalmopathy. New England Journal of Medicine2010;362(8):726-38.">Bahn 2010</a>). Clinically this may result in periorbital oedema, lid lag and retraction, chemosis, exophthalmos and dysmotility. Severe TAO leads to exposure keratopathy and compressive optic neuropathy, which might lead to visual loss. Even milder forms of ophthalmopathy have a great impact on the quality of life of those affected (<a href="./references#CD009226-bbs2-0037" title="KahalyGJ , PetrakF , HardtJ , PitzS , EgleUT . Psychosocial morbidity of Graves' orbitopathy. Clinical Endocrinology2005;63(4):395-402.">Kahaly 2005</a>; <a href="./references#CD009226-bbs2-0043" title="LeeTH , SundarG . Quality of life in thyroid eye disease: a systematic review. Ophthalmic Plastic and Reconstructive Surgery2020 ;36(2):118-26.">Lee 2020</a>). </p> <p>The pathophysiology of TAO is still incompletely understood but appears to involve both the humoral and cell‐mediated immune responses (<a href="./references#CD009226-bbs2-0033" title="HanR , SmithTJ . T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology2006;147(1):13-9.">Han 2006</a>). Orbital fibroblasts are thought to be key players in the condition. Stimulation by inflammatory cytokines causes the fibroblasts to secrete large quantities of the glycosaminoglycan hyaluronan (<a href="./references#CD009226-bbs2-0052" title="PrabhakarBS , BahnRS , SmithTJ . Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocrine Reviews2003;24(6):802-35.">Prabhakar 2003</a>), a chief component of the extracellular matrix, and a subgroup of orbital fibroblasts that can differentiate into mature adipocytes (<a href="./references#CD009226-bbs2-0062" title="SoriskyA , PardasaniD , GagnonA , SmithTJ . Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. Journal of Clinical Endrocrinology and Metabolism1996;81(9):3428-31.">Sorisky 1996</a>). This leads to an increase in the volume of the intraorbital contents. Thyrotropin receptor autoantibodies (TRAb) and immunoglobulins targeting the IGF‐1 receptor also directly activate pre‐adipogenic fibroblasts with the additional secretion of pro‐inflammatory cytokines and glycosaminoglycans (<a href="./references#CD009226-bbs2-0026" title="EcksteinAK , JohnsonKT , ThanosM , EsserJ , LudgateM . Current insights into the pathogenesis of Graves' orbitopathy. Hormone and Metabolic Research2009;41(6):456-64.">Eckstein 2009</a>; <a href="./references#CD009226-bbs2-0030" title="EzraDG , Krell, J, RoseGE , BasilyM , StebbingJ , CastellanoL . Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. Journal of Clinical Pathology2012;65(7):608-13.">Ezra 2012</a>).  </p> <p>Current treatment options for TAO include oral or intravenous glucocorticoids (<a href="./references#CD009226-bbs2-0041" title="KrassasGE , GogakosA , BoboridisK . Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today. Paediatric Endocrinology Reviews2010;7(Suppl 2):204-9.">Krassas 2010a</a>), orbital radiation (<a href="./references#CD009226-bbs2-0053" title="RajendramR , BunceC , LeeRW , MorleyAM . Orbital radiotherapy for adult thyroid eye disease [ ]. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007114. [DOI: 10.1002/14651858.CD007114.pub2]">Rajendram 2012</a>), surgical decompression (<a href="./references#CD009226-bbs2-0019" title="BoboridisKG , BunceC . Surgical orbital decompression for thyroid eye disease. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD007630. [DOI: 10.1002/14651858.CD007630.pub2]">Boboridis 2011</a>) or a combination of these. There is also emerging evidence that the anti‐oxidant selenium may play a role in the medical management of mild TAO (<a href="./references#CD009226-bbs2-0045" title="MarcocciC , KahalyGJ , KrassasGE , BartalenaL , PrummelM , StahlM , et al. Selenium and the course of mild Graves' orbitopathy. New England Journal of Medicine2011;364(20):1920-31.">Marcocci 2011</a>). The European Group on Graves' Orbitopathy (EUGOGO) has recommended a six‐month course of selenium supplementation for mild TAO cases of relatively short duration (<a href="./references#CD009226-bbs2-0018" title="BartalenaL , BaldeschiL , BoboridisK , EcksteinA , KahalyG , MarocciC , et al. The 2016 European Thyroid Association/European Group on graves’ orbitopathy guidelines for the management of graves’ orbitopathy. European Thyroid Journal2016;5(1):9-26.">Bartalena 2016</a>, <a href="./references#CD009226-bbs2-0029" title="European Group on Graves' Orbitopathy (EUGOGO), WiersingaWM , PerrosP , KahalyGJ , MouritsMP , BaldeschiL , et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology2006;155(3):387-9.">EUGOGO 2006</a>). Glucocorticoids are the mainstay of immunosuppressive therapy of TAO, with intravenous pulse administration being preferable in terms of efficacy and side effect profile (<a href="./references#CD009226-bbs2-0064" title="Stiebel-KalishH , RobenshtokE , HasanreisogluM , EzrachiD , ShimonI , LeiboviciL . Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism2009;94(8):2708-16.">Stiebel‐Kalish 2009</a>), although the optimum dose is still subject to investigation (<a href="./references#CD009226-bbs2-0017" title="BartalenaL , KrassasGE , WiersingaW , MarcocciC , SalviM , DaumerieC , et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2012;97(12):4454-63.">Bartalena 2012</a>). The role of orbital radiotherapy for people with the active disease remains controversial, but a Cochrane Review does support its use as monotherapy for moderate TAO (<a href="./references#CD009226-bbs2-0053" title="RajendramR , BunceC , LeeRW , MorleyAM . Orbital radiotherapy for adult thyroid eye disease [ ]. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD007114. [DOI: 10.1002/14651858.CD007114.pub2]">Rajendram 2012</a>) and two studies suggest radiotherapy and intravenous glucocorticoids as dual therapy are more effective than glucocorticoid monotherapy (<a href="./references#CD009226-bbs2-0015" title="BartalenaL , MarcocciC , ChiovatoL , LaddagaM , LepriG , AndreaniD , et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. Journal of Clinical Endocrinology and Metabolism1983;56(6):1139-44.">Bartalena 1983</a>; <a href="./references#CD009226-bbs2-0048" title="NgCM , YuenHK , ChoiKL , ChanMK , YuenKT , NgYW . Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. Hong Kong Medical Journal2005;11(5):322-30.">Ng 2005</a>). In the case of both glucocorticoids and orbital radiotherapy, their impact on the course and final outcome of the disease is not yet determined and recurrences are common after discontinuation of treatment (<a href="./references#CD009226-bbs2-0046" title="MarrociC , BartanelaL , TandaML , ManettiL , Dell'UntoE , RocchiR , et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blinded randomized study. Journal of Clinical Endocrinology and Metabolism2001;86(8):3562-7.">Marocci 2001</a>; <a href="./references#CD009226-bbs2-0076" title="ZoumalanCI , CockerhamKP , TurbinRE , VolpeNJ , KazimM , DouglasRS , et al. Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. Journal of Neuro-Opthalmology2007;27(3):205-14.">Zoumalan 2007</a>). There are new emerging immunomodulatory medical therapies such as tocilizumab, an anti‐interleukin‐6 receptor monoclonal antibody, and teprotumumab, a human monoclonal antibody inhibitor of IGF‐1 receptor. Both have shown promising results in reducing proptosis and the Clinical Activity Score (<a href="./references#CD009226-bbs2-0060" title="SmithTJ , KahalyGJ , EzraDG , FlemingJC , DaileyRA , TangRA , et al. Teprotumumab for thyroid-associated ophthalmopathy. New England Journal of Medicine2017;376(18):1748-61.">Smith 2017</a>, <a href="./references#CD009226-bbs2-0024" title="DouglasRS , KahalyGJ , PatelA , SileS , ThompsonEH , PerdokR , et al. Teprotumumab for the treatment of active thyroid eye disease. New England Journal of Medicine2020;382(4):341.">Douglas 2020</a>, <a href="./references#CD009226-bbs2-0013" title="AzzamSH , KangS , SalviM , EzraDG . Tocilizumab for thyroid eye disease. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012984. [DOI: 10.1002/14651858.CD012984.pub2]">Azzam 2018</a>; <a href="./references#CD009226-bbs2-0050" title="Perez-MoreirasJV , Gomez-ReinoJJ , ManeiroJR , Perez-PampinE , Romo LopezA , Rodríguez AlvarezFM , et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. American Journal of Ophthalmology2018;195:181.">Perez‐Moreiras 2018</a>). Surgical treatment includes orbital decompression, strabismus surgery and eyelid surgery. The indications for surgical decompression are sight‐threatening TAO (with the aim of preserving the optic nerve function) and late‐stage rehabilitative reconstructive surgery after the disease has burnt out (<a href="./references#CD009226-bbs2-0016" title="BartalenaL , BaldeschiL , DickinsonAJ , EcksteinA , Kendall-TaylorP , MarocciC , et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid2008;18(3):333-46.">Bartalena 2008</a>). </p> </section> <section id="CD009226-sec-0011"> <h3 class="title" id="CD009226-sec-0011">Description of the intervention</h3> <p>Rituximab (RTX) is a human/murine chimeric monoclonal antibody that targets CD20, a transmembrane protein expressed on the surface of pre‐B and mature B lymphocytes, but not on stem cells, pro‐B lymphocytes or plasma cells (<a href="./references#CD009226-bbs2-0054" title="ReffME , CarnerK , ChambersKS . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood1994;83(2):435-45.">Reff 1994</a>; <a href="./references#CD009226-bbs2-0059" title="ShenS , ChanA , SfikakisPP , Hsiu LingAL , DetorakisET , BoboridisKG , et al. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Survey of Ophthalmology2013;58(3):252-65.">Shen 2013</a>). The binding of rituximab to CD20 antigen, therefore, blocks the activation and differentiation of B‐cells, and in so doing, leads to specific elimination of B cells without affecting their regeneration from stem cells and the production of immunoglobulins from plasma cells.  </p> <p>Rituximab, sold under the trade names Rituxan and MabThera, was developed by IDEC Pharmaceuticals in 1986. It first received US Food and Drug Administration (FDA) approval in 1997 for the treatment of non‐Hodgkin B‐cell lymphoma resistant to other chemotherapy agents (<a href="./references#CD009226-bbs2-0021" title="BoyeL , ElterT , EngertA . An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology2003;14(4):520-35.">Boye 2003</a>). It is currently approved by the European Medicines Agency (EMA) and FDA for use (with restrictions) in the treatment of people with non‐Hodgkin's lymphoma (follicular and large B‐cell) (<a href="./references#CD009226-bbs2-0039" title="KeatingGM . Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs2010;70(11):1445-76.">Keating 2010</a>), chronic lymphocytic leukaemia (CLL), severe rheumatoid arthritis (<a href="./references#CD009226-bbs2-0061" title="SmolenJS , KeystoneEC , EmeryP , BreedveldFC , BetteridgeN , BurmesterGR , et al. Consensus Statement on the use of rituximab in patients with rheumatoid arthritis. Annals of Rheumatic Diseases2007;66(2):143-50.">Smolen 2007</a>), granulomatosis with polyangiitis (GPA or Wegener’s granulomatosis) and microscopic polyangiitis (MPA), and moderate to severe pemphigus vulgaris. </p> <p>Rituximab is administered by intravenous infusion. </p> </section> <section id="CD009226-sec-0012"> <h3 class="title" id="CD009226-sec-0012">How the intervention might work</h3> <p>There are a number of proposed theories as to how rituximab may work in TAO. Rituximab works by depleting B‐cells, the precursors of the autoantibody‐producing plasma cells. Some authors have suggested that, since Graves' disease is in part an autoantibody‐mediated disease involving TRAb, it is through this mechanism that there may be a potential benefit of rituximab therapy in this condition (<a href="./references#CD009226-bbs2-0034" title="HasselbachHC . B-cell depletion with rituximab - a targeted therapy in Graves' disease and autoimmune thyroiditis. Immunology Letters2003;88(1):85-6.">Hasselbach 2003</a>; <a href="./references#CD009226-bbs2-0070" title="WangSH , BakerJR . Targeting B cells in Graves' disease. Endocrinology2006;147(10):4559-60.">Wang 2006</a>). Studies have suggested that TRAb levels decrease following B‐cell depletion to a similar extent to that seen following treatment with methimazole or prednisolone (<a href="./references#CD009226-bbs2-0003" title="El FassiD , NielsenCH , BonnemaSJ , HasselbachHC , HegedüsL . B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. Journal of Clinical Endocrinology and Metabolism2007;92(5):1769-72. El FassiD , NielsenCH , HasselbalchHC , HegedüsL . Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid2006;16(7):709-10. El FassiD , NielsenCH , KjeldsenJ , ClemmensenO , HegedüsL . Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut2008;57(5):714-5. ">El Fassi 2007</a>; <a href="./references#CD009226-bbs2-0004" title="HeemstraKA , ToesRE , SepersJ , PereiraAM , CorssmitEP , HuizingaTW , et al. Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology2008;159(5):609-15. ">Heemstra 2008</a>; <a href="./references#CD009226-bbs2-0008" title="BonaraP , VannucchiG , CampiI , RossiS , CantoniF , FrugoniC , et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clinical Reviews in Allergy and Immunology2008;34(1):118-23. SalviM , VannucchiG , CampiI , CurròN , DazziD , SimonettaS , et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology2007;156(1):33-40. SalviM , VannucchiG , CampiI , CurròN , SimonettaS , CoveliD , et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clinical Immunology2009;131(2):360-5. SalviM , VannucchiG , CampiI , RossiS , BonaraP , SbrozziF , et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology2006;154(4):511-7. ">Salvi 2007</a>). </p> <p>B‐cells are highly efficient antigen‐presenting cells (APCs) (<a href="./references#CD009226-bbs2-0042" title="LanzavecchiaA . Antigen-specific interaction between T and B cells. Nature1985;314(6011):537-9.">Lanzavecchia 1985</a>) and clinical trials of rituximab in T‐cell‐mediated immunity have shown that rituximab targets the APC functions of B‐cells (<a href="./references#CD009226-bbs2-0051" title="PescovitzMD , GreenbaumCJ , Krause-SteinraufH , BeckerDJ , GitelmanSE , GolandR , et al Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. New England Journal of Medicine2009;361(22):2143-52.">Pescovitz 2009</a>). Attenuation of antigen‐presentation by B‐cells is a possible explanation for the clinical effect of rituximab in TAO, which is a T‐cell‐mediated process. </p> <p>B‐cells are also capable of producing a variety of cytokines, and some of these may be involved in the mechanism of action of rituximab in TAO. In rheumatoid arthritis, for example, B‐cell depletion results in the elevation of IL‐8 levels (<a href="./references#CD009226-bbs2-0040" title="KerenZ , Braun-MoscoviciY , MarkovitsD , RozinA , NahirM , Balbir-GurmanA , et al. Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network. Clinical Immunology2009;113(1):108-16.">Keren 2009</a>). </p> <p>Furthermore, B‐cell depletion in TAO may lead to clinical benefit through altered levels of T<sub>regs</sub>, unique T‐cells that can modulate autoimmune responses (<a href="./references#CD009226-bbs2-0044" title="LiossisSN , SfikakisPP . Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clinical Immunology2008;127(3):280-5.">Liossis 2008</a>; <a href="./references#CD009226-bbs2-0068" title="VignaliDA , CollinsonLW , WorkmanCJ . How regulatory T cells work. Nature Reviews Immunology2008;8(7):523-32.">Vignali 2008</a>). Their impact on human immunity remains uncertain, but they seem to act in a large part through the transforming growth factor‐beta pathway. Their frequency is reduced in autoimmune diseases. Rheumatoid arthritis improves with B‐cell depletion in patients demonstrating increasing levels of T<sub>regs</sub> (<a href="./references#CD009226-bbs2-0020" title="BoissierMC , AssierE , BitonJ , DenysA , FalgaroneG , BessisN . Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine2009;76(1):10-4.">Boisser 2009</a>; <a href="./references#CD009226-bbs2-0055" title="ReisEA , AthanazioDA , LimaI , Oliveira e SilvaN , AndradeJC , JesusRN , et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatology International2009;29(4):469-75.">Reis 2009</a>). </p> <p>Preliminary work has shown that blocking the CD20 receptor on B‐lymphocytes with rituximab affects the clinical course of TAO by reducing inflammation and the degree of proptosis (<a href="./references#CD009226-bbs2-0027" title="El FassiD , NielsenCH , HasselbalchHC , HegedüsL . Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid2006;16(7):709-10.">El Fassi 2006</a>; <a href="./references#CD009226-bbs2-0057" title="SalviM , VannucchiG , CampiI , RossiS , BonaraP , SbrozziF , et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology2006;154(4):511-7.">Salvi 2006</a>). It has been shown that the reduction of B‐cells infiltrating affected tissues is an important indicator of successful rituximab therapy in other disease processes (<a href="./references#CD009226-bbs2-0038" title="KavanaughA , RosengrenS , LeeSJ , HammakerD , FiresteinGS , KalunianK , et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Annual of Rheumatological Disease2008;67(3):402-8.">Kavanaugh 2008</a>). In TAO, it has been shown that depletion of intra‐orbital CD20 lymphocytes, proven through immunohistochemical analyses of orbital tissue, is associated with clinical improvement with rituximab treatment (<a href="./references#CD009226-bbs2-0005" title="KhannaD , ChongKK , AfifiyanNF , HwangCJ , LeeDK , GarneauHC , et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology2010;117(1):133-9. ">Khanna 2010</a>; <a href="./references#CD009226-bbs2-0058" title="SalviM , VannucchiG , CampiI , CurròN , SimonettaS , CoveliD , et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clinical Immunology2009;131(2):360-5.">Salvi 2009</a>). </p> </section> <section id="CD009226-sec-0013"> <h3 class="title" id="CD009226-sec-0013">Why it is important to do this review</h3> <p>Thyroid‐associated ophthalmopathy is the most common extrathyroidal manifestation of Graves' disease and a serious and potentially sight‐threatening one. Current treatment methods include glucocorticoids, radiotherapy and surgery. However, it is unclear whether these treatments alter the natural course of the condition, and relapses are common. In addition, many patients suffer significant complications of treatment with high‐dose intravenous and oral corticosteroids, which are often needed for prolonged periods of time. This means that there is a real, unmet clinical need for effective steroid‐sparing agents that are effective in TAO. Rituximab is a biological agent that has been used successfully in other autoimmune conditions including rheumatoid arthritis. Although the use of rituximab in severe cases of TAO has increased in recent years, the evidence for its use is still in its infancy and, as such, no guidelines have been published outlining recommendations. It is therefore important to review systematically all the evidence that is currently available, as well as any new evidence, to allow for robust conclusions to be made regarding the use of rituximab in the management of this condition. The increasing number of emerging medical therapy options such as teprotumumab and tocilizumab highlights the need for a thorough review of the evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009226-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009226-sec-0014"></div> <p>This review, originally published in 2013 and updated in 2021, assesses the efficacy and safety of using rituximab for the treatment of TAO. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009226-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009226-sec-0015"></div> <section id="CD009226-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009226-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of rituximab for the treatment of people with TAO in this review. </p> </section> <section id="CD009226-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies with adult participants (age 18 years and over) with active TAO.</p> </section> <section id="CD009226-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies of rituximab treatment by intravenous infusion using any dosage regimen, compared with placebo or intravenous glucocorticoid treatment. </p> </section> <section id="CD009226-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated primary and secondary outcomes as follows.</p> <section id="CD009226-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for this review was improvement in thyroid‐associated CAS after treatment. </p> <p>CAS is a validated scoring system, designed to distinguish inflammatory from non‐inflammatory TAO, with a high predictive value for the outcome of immunosuppressive treatment in TAO patients (<a href="./references#CD009226-bbs2-0047" title="MouritsMP , PrummelMF , WiersingaWM , KoornneefL . Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology1997;47(1):9-14.">Mourits 1997</a>). It is based on the classical signs of acute inflammation (pain, redness, swelling, and impaired function). After the first clinical examination, a score out of seven is given. After two consecutive clinical examinations, an activity score can be determined, ranging from nought to 10 points, including three points that rely on assessing the changes in the disease status.  </p> </section> <section id="CD009226-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcomes for this review were the following after treatment:</p> <p> <ol id="CD009226-list-0001"> <li> <p>Improvement in NOSPECS* TAO classification score</p> </li> <li> <p>Decrease in proptosis (mm)</p> </li> <li> <p>Change in palpebral aperture measurement (mm)</p> </li> <li> <p>Improvement in extraocular motility (degrees or diplopia rating scale)</p> </li> <li> <p>Improvement in quality of life score</p> </li> </ol> </p> <p>We also collected safety outcomes, including adverse events.</p> <p>*The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C. </p> <p><b>Follow‐up time points</b> </p> <p>We planned that the time points for all outcomes would be at 4, 6 and 12 months post‐treatment. The ranges of follow‐up time points were from 6 to 18 months in this review. </p> </section> </section> </section> <section id="CD009226-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009226-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist searched the following electronic databases for RCTs and controlled clinical trials. There were no language or publication year restrictions. We last searched the electronic databases on 22 February 2022. </p> <p> <ul id="CD009226-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 2) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 22 February 2022) (<a href="./appendices#CD009226-sec-0086">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 22 February 2022) (<a href="./appendices#CD009226-sec-0087">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 22 February 2022) (<a href="./appendices#CD009226-sec-0088">Appendix 3</a>). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database) (1982 to 22 February 2022) (<a href="./appendices#CD009226-sec-0089">Appendix 4</a>). </p> </li> <li> <p>ISRCTN registry (<a href="https://iscrtn.org" target="_blank">https://iscrtn.org</a>); searched 22 February 2022 (<a href="./appendices#CD009226-sec-0090">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>); searched 22 February 2022 (<a href="./appendices#CD009226-sec-0091">Appendix 6</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>); searched 22 February 2022 (<a href="./appendices#CD009226-sec-0092">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD009226-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We manually searched the reference lists of review articles and used the Science Citation Index to identify additional studies citing trials. We contacted the lead investigators of relevant trials on ClinicalTrials.gov and WHO ICTRP for information and data from as yet unpublished clinical trials. We contacted experts in the field for information about any ongoing trials. We contacted the manufacturers of rituximab for details of any sponsored trials. We did not search conference proceedings for this review. </p> </section> </section> <section id="CD009226-sec-0026"> <h3 class="title" id="CD009226-sec-0026">Data collection and analysis</h3> <section id="CD009226-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently inspected the titles and abstracts resulting from the electronic and manual searches and classified each record as relevant, potentially relevant or not relevant for this review. We obtained full‐text copies of articles identified as relevant or potentially relevant. Two review authors independently assessed each article and applied the inclusion criteria to determine final eligibility. We resolved discrepancies through discussion and consensus. We documented the excluded studies and reasons for exclusion. </p> </section> <section id="CD009226-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SK and SHA) independently extracted the following data, where available, from included studies. </p> <p> <ol id="CD009226-list-0003"> <li> <p>Methodology (group size, randomisation, blinding (masking), exclusions after randomisation, loss to follow‐up) </p> </li> <li> <p>Participant characteristics (age, sex, thyroid status, TRAb levels, smoking status, thyroid volume (mL), TAO activity (CAS), TAO severity (NOSPECS score)) </p> </li> <li> <p>Intervention (dose, regimen, timing of treatment in relation to diagnosis, timing of treatment in relation to previous interventions, nature of previous interventions) </p> </li> <li> <p>Primary and secondary outcomes (CAS, NOSPECS score, proptosis (mm) and extraocular motility (degrees and diplopia rating scale results) at the start of treatment and at each follow‐up time period) </p> </li> <li> <p>Adverse events and side effects (number, nature, timing)</p> </li> <li> <p>Quality of life scores</p> </li> </ol> </p> <p>Trial authors were contacted, where possible, for more information if data were missing or difficult to interpret. We resolved any discrepancies between authors by discussion and consensus. One review author entered the data into Review Manager 5.4 (<a href="./references#CD009226-bbs2-0056" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>) and the second author checked the entered data for errors or inconsistencies. </p> </section> <section id="CD009226-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SK and SHA) independently assessed the methodological quality of the selected trials according to the methods set out in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Intervention</i> (<a href="./references#CD009226-bbs2-0035" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 . Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). The following six quality parameters were considered in assessing the risk of bias. </p> <p> <ol id="CD009226-list-0004"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Masking of participants and outcome assessors (performance bias and detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective outcome reporting (reporting bias)</p> </li> <li> <p>Other sources of bias</p> </li> </ol> </p> <p>We assessed each parameter as low risk of bias, high risk of bias, or unclear risk of bias. We resolved discrepancies between review authors by discussion and consensus. </p> </section> <section id="CD009226-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We reported continuous variables where the data were normally distributed as mean and standard deviation (SD), and where the data were not normally distributed as median and interquartile range (IQR).  We planned to report the standardised mean difference (SMD) if the included studies reported the same outcomes but on different valid rating scales. We reported dichotomous variables as risk ratios (RRs) with 95% confidence intervals (CIs). These included any rating scales that were dichotomized based on a clinically relevant cut‐off point and the proportion of participants experiencing each adverse event or side effect. </p> </section> <section id="CD009226-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The treatment is a systemic treatment and as such affects both eyes of each person treated. For this reason, participants rather than eyes were randomised. The CAS and NOSPECS scores were calculated for each participant and so the unit of analysis for these data was the participant. For proptosis, palpebral aperture and extraocular motility data, the unit of analysis was the individual eye. Where studies presented worse eye data, we analysed these separately. Where studies presented individual eye data, we considered these in a separate analysis. The unit of analysis was the participant for demographic characteristics and quality‐of‐life data.  </p> <p>For eligible cluster‐randomised trials, we planned to conduct the analysis at the same level as the allocation. This approach, however, may have reduced the precision of the effect estimate. Statistical analysis at the level of the individual can lead to an inappropriately high level of precision unless methods are used to account for the clustering in the data. Effect estimates and their standard errors from correct analyses of cluster‐randomised trials may be meta‐analysed using the generic inverse‐variance approach. </p> <p>Had any crossover trials been identified, we would have assessed whether a crossover trial is a suitable method for the condition and intervention in question. We planned to consider different approaches and select the most appropriate method where possible. A possible approach would be to take all measurements from intervention periods and analyse these as if the trial were a parallel‐group trial. Another approach would be to include only data from the first period. We could have attempted to approximate a paired analysis by imputing missing standard deviations. </p> <p>To include a study with more than two intervention groups in a meta‐analysis, a recommended approach is (i) to omit groups that are not relevant to the comparison being made, and (ii) to combine multiple groups that are eligible as the experimental or comparator intervention to create a single pair‐wise comparison. Alternatively, multi‐arm studies are dealt with appropriately by network meta‐analysis. </p> </section> <section id="CD009226-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, we contacted the authors to obtain this information. Any missing data that was unobtainable were assumed to be 'missing at random' and 'complete case' analysis was performed. </p> </section> <section id="CD009226-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We did not assess the between‐study heterogeneity.</p> <p>Had we identified sufficient trials, we would have assessed heterogeneity by examining the study characteristics and forest plots of the results. We would have used the I<sup>2</sup> statistic to assess the impact of statistical heterogeneity, interpreting an I<sup>2</sup> value of 50% or more as substantial. </p> </section> <section id="CD009226-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Had we identified sufficient trials for this update, we would have used a funnel plot to examine publication bias. </p> </section> <section id="CD009226-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Meta‐analysis was not possible in this review as there was only one study for each comparison. Had we identified sufficient trials with substantial clinical or statistical heterogeneity between them (I<sup>2</sup> &gt; 50%), rather than combining the results, we would have presented an estimate of effect and associated CI for each individual trial. Had we identified sufficient trials with little variation between them, we would have combined the results in a meta‐analysis using a random‐effects model, or a fixed‐effect model if there were very few trials. </p> </section> <section id="CD009226-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Had we identified sufficient trials, we would have: (i) performed subgroup analyses to identify possible sources of heterogeneity and (ii) stratified by treatment dosage and thyroid status, as both are potential effect modifiers. </p> </section> <section id="CD009226-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Had sufficient data been available, we would have conducted sensitivity analyses to determine the impact of the exclusion of studies with lower methodological quality and industry‐funded studies. </p> </section> <section id="CD009226-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The GRADE approach incorporates assessment of indirectness, study limitations, inconsistency, publication bias and imprecision. We assessed the certainty of the evidence (high, moderate, low, and very low) using these five GRADE considerations and, if required, downgraded the evidence by one, two or three levels using assessments at each stage of our analysis. This approach gives an overall measure of how certain we can be that our estimate of effect is correct.  </p> <p>One review author (SK) used GRADEpro software (<a href="./references#CD009226-bbs2-0032" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 15 February 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>), to create a 'Summary of findings' table for each comparison (<a href="http://www.guidelinedevelopment.org/" target="_blank">www.guidelinedevelopment.org/</a>). A second author (SHA) assessed the judgements made and consensus was reached through discussion. </p> <p>The two comparisons are included in the summary of findings tables: </p> <p>1. Rituximab compared to IV methylprednisolone for thyroid‐associated ophthalmopathy. </p> <p>2. Rituximab compared to placebo for thyroid‐associated ophthalmopathy. </p> <p>The following outcomes are presented in the summary of findings tables: </p> <p>1. CAS at 24 weeks</p> <p>2. NOSPECS</p> <p>3. Proptosis</p> <p>4. Palpebral aperture</p> <p>5. Motility</p> <p>6. Quality of life</p> <p>7. Adverse events </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009226-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009226-sec-0039"></div> <section id="CD009226-sec-0040"> <h3 class="title">Description of studies</h3> <p>Two prospective, randomised, double‐masked trials are included in this review, one comparing rituximab with IVMP and the other with placebo.  </p> <section id="CD009226-sec-0041"> <h4 class="title">Results of the search</h4> <p>The original searches were undertaken in April 2013 (<a href="./references#CD009226-bbs2-0077" title="MinakaranN , EzraDG . Rituximab for thyroid-associated ophthalmopathy (Review). Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD009226. [DOI: 10.1002/14651858.CD009226.pub2]">Minakaran 2013</a>), and yielded a total of 524 references (Figure 1). The Trials Search Co‐ordinator scanned the search results, removed duplicates and removed 148 references which were not relevant to the scope of the review. We screened the remaining 308 reports to identify potentially relevant studies. We obtained and read 13 full‐text copies of papers reporting on eight studies. None of these were suitable for inclusion. See <a href="./references#CD009226-sec-0103" title="">Characteristics of excluded studies</a> for details. </p> <p>An updated electronic search in February 2022 identified a further 648 reports of studies (<a href="#CD009226-fig-0001">Figure 1</a>). The Cochrane Eyes and Vision Information Specialist removed 137 duplicates, pre‐screened 511 records and removed 447 references which were not relevant to the scope of the review. We screened the remaining 64 reports and obtained four full‐text reports of studies of potential interest. Of these, two studies were deemed suitable for inclusion (<a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>; <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>). There are two ongoing RCTs (<a href="./references#CD009226-bbs2-0012" title="EUCTR2011-000899-33-SE. Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2011-000899-33-SE+  accessed 3 March 2022. ">EUCTR2011‐000899‐33‐SE</a>; <a href="./references#CD009226-bbs2-0011" title="ChiCTR2000036239. A prospective clinical study of monoclonal antibody treatment for refractory thyroid-associated ophthalmopathy. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000036239 accessed 3 March 2022. ">ChiCTR2000036239</a>) that are likely to meet the inclusion criteria for the review when the results are available in the future. We will assess these studies for potential inclusion when complete.  </p> <div class="figure" id="CD009226-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD009226-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_n/nCD009226-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD009226-sec-0042"> <h4 class="title">Included studies</h4> <p>Two studies were included in this review. </p> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> conducted a prospective, randomised, double‐masked trial comparing rituximab (RTX) to intravenous methylprednisolone (IVMP). They included people with active TAO (CAS ≥ 3 out of 7 or 4 out of 10) that was moderate to severe according to the NOSPECS scheme. Participants were randomised to receive either IVMP (7.5 g) or RTX (2000 or 500 mg). One participant randomised to receive RTX subsequently withdrew from the study. The trial authors had initially planned to recruit 60 participants (30 RTX and 30 IVMP). However, the study was discontinued based on an interim analysis on 32 participants (16 RTX and 16 IVMP) that showed a high proportion of disease reactivation in the IVMP group. The study was supported by the Italian Ministry of Education, University and Research, Rome, Italy, and by <i>Fondazione Ca' Granda Istituto di Ricovero e Cura a Carattere Scientifico</i> (Ca' Granda research hospital), Milan, Italy.  </p> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> performed a prospective, randomised, double‐masked trial comparing rituximab to placebo. Twenty‐five people with active (defined as CAS of 4 of 7 or greater) moderate to severe Graves’ orbitopathy were enrolled (13 RTX and 12 placebo), and 21 completed the study to the primary endpoint. The participants were given either two rituximab infusions (1000 mg each) or two saline infusions two weeks apart. The study was funded by the National Institutes of Health (NIH). Please see the '<a href="./references#CD009226-sec-0102" title="">Characteristics of included studies</a>' table for further details. </p> <section id="CD009226-sec-0043"> <h5 class="title">Participants</h5> <p>The two included studies comprised a total of 56 adult participants with active TAO. In the study comparing RTX with IVMP, there were 15 people in the RTX group and 16 in the IVMP group. In the study comparing RTX with placebo, there were 13 RTX and 12 placebo participants. Forty‐three participants (77%) in the two included studies were female. <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> included younger participants (mean age of 51 years compared with 57.6 years in <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>). In addition, <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> included a higher proportion of smokers (56.2% and 66.7% in the IVMP and RTX groups, respectively, compared with 16.7% and 15.4% in the placebo and RTX groups, respectively, in <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>). Duration of TAO was much shorter in <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>, with a mean of 4.6 (SD 2.6) months and 4.5 (SD 2.9 months in the IVMP and RTX groups, respectively, compared to a median of 299 (interquartile range (IQR 253 to 595) days and 373 (IQR 240 to 1080) days in the placebo and RTX groups, respectively, in <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>. The mean baseline CAS was 4.4 (SD 0.7) points in the RTX group in <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> versus 4.9 (SD 1) points in <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>. Both studies mandated a period of steroid cessation (at least 12 weeks for <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> and 4 weeks for <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>) prior to enrolment. </p> </section> <section id="CD009226-sec-0044"> <h5 class="title">Types of interventions</h5> <p>One study (<a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>) compared intravenous RTX to intravenous methylprednisolone (IVMP) and another (<a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>) compared intravenous RTX to intravenous saline (placebo). Both studies gave 1 g of RTX twice with a two‐week interval, although the dose was reduced to a single 500 mg of RTX after the first 12 participants in <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> based on the evidence of complete B cell depletion from a very low dose of RTX (100 mg). The study with the IVMP control group (<a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>) followed the EUGOGO protocol of a treatment schedule with weekly 830 mg IVMP administered for 6 weeks followed by 415 mg for another 6 weeks for a cumulative dose of 7.47 g. </p> </section> <section id="CD009226-sec-0045"> <h5 class="title">Types of outcome measures</h5> <p>In <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>, the primary outcome was a decrease in CAS by 2 or more points or disease inactivation defined as CAS below 3 points at 24 weeks.  </p> <p>The secondary endpoints were the following signs of disease severity.</p> <p> <ol id="CD009226-list-0005"> <li> <p>Reduction in NOSEPECS by at least 2 classes</p> </li> <li> <p>Decrease in proptosis by at least 2 mm</p> </li> <li> <p>Reduction in lid fissure width by at least 3 mm</p> </li> <li> <p>Improvement in total eye score (TES) (obtained by multiplying each NOSPECS class by the severity grade) </p> </li> <li> <p>Improvement in eye motility according to the Gorman score for diplopia by 1 class or greater, eye muscle duction by 8 degrees or greater measured with the Foerster‐Goldman perimeter, and the total motility score (TMS) </p> </li> <li> <p>Disease reactivation at 24 weeks and the number of surgical procedure required after 12 months </p> </li> <li> <p>Improvement in either function or appearance components of the Graves’ ophthalmopathy quality of life questionnaire (GO‐QoL) by at least 6 points when compared to baseline. </p> </li> </ol> </p> <p>NOSPECS score and adverse events related to either treatment were also documented. Most outcomes were recorded at 6 months and 12 months follow‐up. Residual disease severity and requirement for further treatment were evaluated at 18 months. </p> <p>For <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>, the primary endpoint of interest was CAS reduction assessed as a continuum and separately as an improvement by 2 or more points. </p> <p>The secondary endpoints were as follows.</p> <p> <ol id="CD009226-list-0006"> <li> <p>Success rate (defined as a decrease in CAS by 2 or more points and no additional therapy)</p> </li> <li> <p>Change in lid fissure width</p> </li> <li> <p>Change in lagophthalmos</p> </li> <li> <p>Change in proptosis</p> </li> <li> <p>Change in orbital fat and/or muscle volume by CT</p> </li> <li> <p>Change in subjective diplopia score according to the Gorman scale</p> </li> <li> <p>Change in quality of life according to the Physical and Mental Component Summary scores of the Medical Outcomes Study 12‐Item Short Form Health Survey (SF‐12).  </p> </li> </ol> </p> <p>Additionally, NOSPECS scores and adverse reactions were recorded. The outcome measurements were documented at 6 months and 18 months follow‐up. </p> </section> </section> <section id="CD009226-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Whilst we did not perform a separate electronic search for study designs less rigorous than the RCT, several non‐RCTs, interventional case series and case reports were identified. Given the small number of studies (n = 8) overall looking at rituximab in TAO, these studies are detailed in <a href="./references#CD009226-sec-0103" title="">Characteristics of excluded studies</a>. The additional tables <a href="#CD009226-tbl-0003">Table 1</a>, <a href="#CD009226-tbl-0004">Table 2</a>, <a href="#CD009226-tbl-0005">Table 3</a>, and <a href="#CD009226-tbl-0006">Table 4</a> describe the excluded studies which are non‐randomised controlled trials, non‐randomised case series, case reports, and a meta‐analysis, respectively. </p> <div class="table" id="CD009226-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Non‐randomised controlled trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009226-bbs2-0003" title="El FassiD , NielsenCH , BonnemaSJ , HasselbachHC , HegedüsL . B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. Journal of Clinical Endocrinology and Metabolism2007;92(5):1769-72. El FassiD , NielsenCH , HasselbalchHC , HegedüsL . Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid2006;16(7):709-10. El FassiD , NielsenCH , KjeldsenJ , ClemmensenO , HegedüsL . Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut2008;57(5):714-5. ">El Fassi 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with newly diagnosed or relapsed untreated Grave's disease<br/>  </p> <p>RTX group: 10 participants.</p> <p>Control group: 10 participants</p> <p>18 women, 2 men</p> <p>Age range: 18 to 65 years</p> <p>No participants had received immunosuppressants.</p> <p>Consecutive eligible people offered RTX and control participants were those who declined</p> <p> </p> <p>Only 2 participants in RTX group and no participants in control group had active TAO:</p> <p>Participant 1: woman, aged 64, ex‐smoker; CAS 6</p> <p>Participant 2: woman, aged 35, ex‐smoker; CAS 4/5 (right/left)</p> <p> </p> <p>Follow‐up:</p> <p>RTX group: 740 (435 to 904) days</p> <p>Control group: 554 (99 to 741) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants rendered euthyroid with methimazole for 4 months</p> <p>RTX group: RTX IV infusion 375 mg per m<sup>2</sup> body surface area on day 1, 8, 15 and 22 </p> <p>Pretreatment with 1 g oral acetaminophen, 2 mg IV clemastine</p> <p>Control group: no further treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to relapse of hyperthyroidism</p> <p>Changes in autoantibody level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 patients in RTX group remained in remission with median follow‐up 705 days</p> <p>All participants in control group relapsed by 393 days (P &lt; 0.05)</p> <p>All participants in remission had initial TRAb levels below 5 IU/litre</p> <p>None of 5 participants in control group with corresponding low TRAb levels stayed in remission (P &lt; 0.01) </p> <p> </p> <p>2 participants in RTX group with active TAO:</p> <p>Participant 1: CAS reduced from 6 to 2 in 8 months; proptosis reduced from 25 mm to 22 mm bilaterally. </p> <p>Participant 2: CAS 4/5 (right/left) reduced to 2/3 at 5 weeks, 2/4 at 5 months and 1/1 at 11 months; proptosis changed from 23 mm bilaterally to 21 mm/23 mm (right/left). </p> <p>Both participants improved in soft tissue changes and eye motility.</p> <p> </p> <p>Adverse effects:</p> <p>After first infusion only: hypotension (n = 4), nausea (n = 2), fever (n = 1), chills (n = 1), and tachycardia (n = 1) </p> <p>2 participants had slight pain in the finger joints</p> <p>1 participant developed ulcerative colitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009226-bbs2-0008" title="BonaraP , VannucchiG , CampiI , RossiS , CantoniF , FrugoniC , et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clinical Reviews in Allergy and Immunology2008;34(1):118-23. SalviM , VannucchiG , CampiI , CurròN , DazziD , SimonettaS , et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology2007;156(1):33-40. SalviM , VannucchiG , CampiI , CurròN , SimonettaS , CoveliD , et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clinical Immunology2009;131(2):360-5. SalviM , VannucchiG , CampiI , RossiS , BonaraP , SbrozziF , et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology2006;154(4):511-7. ">Salvi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment of Graves’ disease and associated ophthalmopathy with the anti‐CD20 monoclonal antibody rituximab: an open study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with Grave's disease and TAO<br/>  </p> <p>RTX group: 9 participants</p> <p>7 women, 2 men</p> <p>Age range: 31 to 51 years.</p> <p>5 smokers, 2 ex‐smokers, 2 non‐smokers</p> <p>2 participants mild signs; 6 moderate; 1 severe<br/>  </p> <p>Steroid group: 20 participants</p> <p>17 women, 3 men</p> <p>Age range: 30 to 82 years</p> <p>12 smokers, 4 ex‐smokers, 4 non‐smokers</p> <p>3 participants mild TAO, 13 moderate, 4 severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTX group: RTX IV infusion 1000 mg over 4 hours 15 minutes, twice with a 2‐week interval. 1 g oral paracetamol and 10 mg oral chlorpheniramine administered prior to RTX treatment. </p> <p>Steroid group: methylprednisolone 500 mg IV once a week for 14 weeks then 250 mg once a week for further 2 weeks </p> <p> </p> <p>Follow‐up:</p> <p>RTX group: 1 participant 5 months, 8 participants 12 months or more</p> <p>Steroid group: 12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in CAS</p> <p>Change in NOSPECS<sup>a</sup> score </p> <p>Thyroid function</p> <p>Lymphocyte count</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTX group:</p> <p>All participants had peripheral B‐cell depletion with first infusion. Depletion lasted 4 months in 3 participants, 5 months in 5 participants, and 1 still depleted at 5 months. </p> <p>Thyroid function not affected</p> <p>Change in TgAb, TPOAb and TRAb not significant and not correlated to CD20+ lymphocyte depletion </p> <p>Mean CAS before 4.7 (SD 0.5), reduced to 1.8 (SD 0.8) at 30 weeks (P &lt; 0.0001)</p> <p>Proptosis (NOSPECS<sup>a</sup> class 3) reduced significantly in participants with active TAO, from 22.4 (SD0.5) to 20.9 (SD0.6) (P &lt; 0.0001) and in Graves' disease with lid signs, from 19.0 (SD 0.7) to 17.3 (SD0.9) (P &lt; 0.003) at 30 weeks </p> <p>Soft tissue inflammation (NOSEPCS<sup>a</sup> 2) decreased significantly (P &lt; 0.001) </p> <p>Degree of motility impairment (NOSPECS<sup>a</sup> 4) reduced (P &lt; 0.05) </p> <p>No relapse at time of B cell return and in subsequent 5 to 7 months of follow up</p> <p>One participant clinically responsive to RTX (no change in TRAb) later had thyroidectomy and orbital decompression. B cells found in thyroid tissue but none in orbital tissue. </p> <p> </p> <p>Steroid group:</p> <p>Mean serum TRAb 16.3 (SD 4.9) U/L before and 9.3 (SD 3.6) U/L after (non‐significant). No difference compared to RTX at 30 weeks. </p> <p>Mean CAS 4.1 (SD 0.03) before and 2.0 (SD0.4) at 30 weeks (P &lt; 0.0001)</p> <p>Significantly more change in CAS with RTX than with IVGC (P &lt; 0.05)</p> <p>Mean proptosis reduced from 22.6 (SD 0.6) to 22.1 (SD 0.6) at 30 weeks (P &lt; 0.014). No significant difference compared to RTX. </p> <p>Soft tissue inflammation decreased significantly at 30 weeks (P &lt; 0.003) but no significant difference compared to RTX </p> <p>4 participants did not respond to IVGC and one underwent acute orbital decompression for optic neuropathy </p> <p>2 participants also had relapse of TAO 6 to 8 weeks after IVGC withdrawal</p> <p> </p> <p>Adverse effects:</p> <p>RTX: minor side effects in 3 participants with first infusion (nose and throat itching, mild temperature elevation) </p> <p>Steroids: adverse effects more frequent (9 participants) and of greater clinical significance (flushing, insomnia, dyspepsia, hyperglycaemia, serum aminotransferases or GGT increase) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>GGT:</b> gamma‐glutamyl transferase; <b>IV:</b> intravenous; <b>IVGC:</b> intravenous glucocorticoids; <b>RTX:</b> rituximab; <b>SD:</b> standard deviation; <b>TAO:</b> thyroid‐associated ophthalmopathy; <b>TgAb:</b> thyroglobulin antibodies; <b>TPOAb:</b> thyroid peroxidase antibodies; <b>TRAb:</b> thyrotropin receptor autoantibodies </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C. </p> </div> </div> <div class="table" id="CD009226-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Non‐randomised case series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0004" title="HeemstraKA , ToesRE , SepersJ , PereiraAM , CorssmitEP , HuizingaTW , et al. Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology2008;159(5):609-15. ">Heemstra 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab in relapsing Graves’ disease, a phase II study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 people with relapsing Graves' disease</p> <p>9 women, 4 men</p> <p>Mean age: 39.5 (SD 9.5) years</p> <p>Previously adequately treated with at least 1 year antithyroid medications</p> <p>Median CAS was 0 (range 0 to 2)</p> <p>3 participants had NOSPECS<sup>a</sup> 2a3040 </p> <p> </p> <p>Follow up: 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX IV infusion 1000 mg, twice with a 2‐week interval.</p> <p>Pre‐medication 10 mg IV dexamethasone plus 2 mg IV clemastine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absence of hyperthyroidism</p> <p>Relapse free survival time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants had decrease in C19 and MS4A1 (lymphocyte populations)</p> <p>4 participants no response</p> <p>Other 9 participants: FT4 decreased at 16 weeks (P = 0.001) and TSH increased (P = 0.011) </p> <p>At follow‐up 14 to 27 months, 9 participants still euthyroid with normal FT4 (P &lt; 0.001) and TSH (P = 0.008) </p> <p> </p> <p>Adverse effects: 2 participants had temporary joint pains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0005" title="KhannaD , ChongKK , AfifiyanNF , HwangCJ , LeeDK , GarneauHC , et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology2010;117(1):133-9. ">Khanna 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab treatment of patients with severe, corticosteroid‐resistant thyroid‐associated ophthalmopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 people with severe progressive TAO unresponsive to steroids</p> <p>4 women, 2 men</p> <p>Mean age: 54.3 (SD 9.1) years</p> <p>3 current smokers</p> <p> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX IV infusion 1000 mg, twice with a 2‐week interval</p> <p>Pre‐medication 100 mg IVMP, 1 g oral acetaminophen plus 50 mg oral diphenhydramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in CAS</p> <p>Change in proptosis</p> <p>Change in strabismus</p> <p>Side effects</p> <p>Quantification of regulatory T cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean CAS improved from 5.5 (SD 0.8) to 1.3 (SD 0.5 )at 2 months after treatment (P &lt; 0.03) </p> <p>CAS remained quiescent in all participants (0.7 (SD 0.8); P &lt; 0.0001) at mean follow‐up of 6.2 (SD 4.5) months </p> <p>Vision improved bilaterally in all 4 participants with dysthyroid optic neuropathy (DON) </p> <p>None of the 6 participants experienced disease relapse after RTX infusion</p> <p>Mean proptosis by Hertel measurement remained stable (24 (SD 3.7) mm before therapy and 23.6 (SD 3.7) mm after therapy (P = 0.17)) </p> <p>1 participant experienced progressive strabismus after RTX treatment</p> <p>No participants had improvement in extraocular motility</p> <p>The abundance of T regulatory cells, assessed in 1 participant who had orbital decompression 12 days after RTX, increased within 1 week of RTX and remained elevated at 18 months of follow‐up </p> <p> </p> <p>Adverse effects: urinary tract infection, hypertension. 1 participant had cardiac arrest and died 3 months after treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0010" title="SilkissRZ , ReierA , ColemanM , LauerSA . Rituximab for thyroid eye disease. Ophthalmic Plastic and Reconstructive Surgery2010;26(5):310-4. ">Silkiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab for thyroid eye disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 people with active TAO (CAS of ≥ 4)</p> <p>7 women, 5 men</p> <p>Age range: 34 to 80 years</p> <p>4 smokers</p> <p>4 participants had never previously been treated with steroids</p> <p> </p> <p>Follow‐up: 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX IV infusion 1000 mg, twice with a 2‐week interval</p> <p>Pre‐medication 1 g oral acetaminophen plus 50 mg oral diphenhydramine</p> <p>Note: 2 participants were still on oral glucocorticoids during the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in CAS</p> <p>Change in thyroid‐associated ophthalmopathy scale (TAOS)</p> <p>Pre‐infusion CD20+ lymphocyte count</p> <p>Post‐infusion CD19+ lymphocyte count</p> <p>Thyroid stimulating hormone and thyroid stimulating immunoglobulin levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean CAS improved from 5.5 (SD 1.2) to 0.8 (SD 1.4) at 52 weeks after treatment (P &lt; 0.001) </p> <p>Mean TAOS improved from 10.4 (SD 5.7) to 2.4 (SD 4.6) at 52 weeks (P &lt; 0.001)</p> <p>No change in TSH or TSI levels before and after treatment</p> <p> </p> <p>Adverse effects: none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0007" title="MitchellA , GanE , MorrisM , JohnsonK , NeohC , DickinsonA , et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves’ orbitopathy. Cinical Endocrinology 2013, Jan 16;79(3):437-42. ">Mitchell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The effect of B cell depletion therapy on anti‐TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves’ orbitopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 people with steroid‐refractory TAO</p> <p>8 women, 1 man</p> <p>Median age: 62 years (range 37 to 87)</p> <p>All participants had pulsed IVMP for a median of 3 months prior to RTX treatment (range 2 weeks to 6 months) </p> <p>8/9 participants had CAS greater than 4/10 (median 6.5, range 4 to 8). 1 participant had CAS 1. </p> <p>4 participants had sight‐threatening TAO (NOSPECS<sup>a</sup> 6) </p> <p> </p> <p>Follow‐up: 16 months or more (median 29 months, range 16 to 46 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX infusion 1000 mg, twice with a 2‐week interval (3 participants), or 500 mg, twice with a 2‐week interval (6 participants) </p> <p>One participant not B cell depleted after second 500 mg infusion so received third 500 mg infusion </p> <p>Premedication 500 mg IVMP, 10 mg IV chlorpheniramine and 1 g oral paracetamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thyroid function tests</p> <p>B cell count</p> <p>Thyroid autoantibody levels</p> <p>Change in CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect on TFTs</p> <p>TBII reduced in all participants</p> <p>CAS improved in all participants</p> <p>Median improvement in CAS at 3 months: 2 points (range 1 to 6), P = 0.018</p> <p>Median improvement in CAS at 12 months: 5 points (range 1 to 8), P = 0.0006</p> <p> </p> <p>Adverse effects: 4 participants had minor side effects following first infusion: 2 headache, 1 headache and chills without pyrexia, 1 mild myalgia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0023" title="Deltour J-B, d’Assigny FlamenM , LadsousM , GiovansiliL , CariouB , CaronP , et al. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study. Graefes Archives for Clinical and Experimental Ophthalmology2020;258(9):2013-21.">Deltour 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 people with moderate to severe TAO who are corticosteroid resistant or corticosteroid dependent </p> <p>21 women, 11 men</p> <p>Mean age: 51.2 (SD 10.7) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants received 2 IV injections of 1 g of RTX 2 weeks apart, with oral paracetamol (1 g), oral antihistamine treatment, and IV glucocorticoid (1 mg/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in at least 1 of the 3 dysfunctional parameters (inflammatory, oculomotor, and visual) without deterioration of the other(s) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of participants presenting signs of inflammatory activity (CAS ≥ 3) significantly diminished (74% before treatment, 45% at 12 weeks (P &lt; 0.05), 29% at 24 weeks (P &lt; 0.001)). </p> <p>The proportion of participants with visual dysfunction significantly diminished (39% before treatment, 19% at 12 weeks, then 16% at 24 weeks (P &lt; 0.05)). </p> <p>1 case had improvement in oculomotor dysfunction.</p> <p>Mean CAS significantly decreased after treatment, from 3.29 (SD 1.16) at week 0 to 1.59 (SD 1.12) at week 24 (P &lt; 0.001). </p> <p> </p> <p>Adverse effect: 1 participant had a cytokine release syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0025" title="Pasquier-Fediaevsky L,  AndreiS ,  Berche M,  Leenhardt L ,  Héron E,  Rivière S. Slow-dose rituximab for active moderate to severe graves' orbitopathy resistant to conventional treatment. Ocular Immunology and Inflammation2019;27(5):844-50.">Du Pasquier‐Fediaevsky 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose rituximab for active moderate to severe graves' orbitopathy resistant to conventional treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 people with active moderate to severe TAO who were resistant to conventional treatment (IVMP, oral corticosteroids and orbital radiotherapy). </p> <p>11 women, 4 men</p> <p>Age: 46 years (range 29 to 58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose RTX infusions (100 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS decreased by 2 points or &lt; 4/10, at 3 to 4 months after the first infusion of RTX </p> <p>Proptosis</p> <p>Lid fissure width</p> <p>Eye motility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 participants received 100 mg RTX doses (cumulative dose 100 to 400 mg)</p> <p>Mean CAS decreased from 4.6 (SD 0.89) to 2.0 (SD 1.65) at 17.1 weeks, after a mean of 2.3 infusions (range 1 to 4) of 100 mg RTX. </p> <p>Mean CAS was 1.3 (SD 1.76) at last visit at 63.6 weeks (range 44.3 to 87.5).</p> <p>RTX was effective in 13 participants, within 2 months of treatment initiation.</p> <p>In all responders except 1, TAO remained inactive after 1 year of follow‐up.</p> <p>RTX was ineffective in 2 participants, according to unchanged CAS after 2 infusions.</p> <p>All participants were euthyroid at the time of RTX treatment.</p> <p>Mean duration between the end of IVMP and RTX treatments was 16 months.</p> <p>Mean duration between the end of orbital radiotherapy and RTX treatments was 15 months.</p> <p>RTX was not clinically significant on proptosis, lid fissure width, and eye motility.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0036" title="Insull E,  Sipkova Z,  DavidJ , TurnerH , NorrisJ . Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment [ ]. Clinical Endocrinology2019;91(1):179-86.">Insull 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 people with active TAO (VISA (vision, inflammation, strabismus, appearance) CAS ≥ 3)   </p> <p>8 women, 4 men</p> <p>Age: 49 years (range 24 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose RTX infusion (100 mg).</p> <p>If clinically indicated, further doses of 500 mg IVMP were administered weekly.</p> <p>Depending on disease activity and severity, a steroid‐sparing agent was started (1st line methotrexate, 2nd line cyclosporin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> <p>VISA overall severity score</p> <p>OX‐TED (Oxford‐Thyroid Eye Disease) QoL scores</p> <p>TSH receptor antibodies</p> <p>B cell subsets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean CAS was significantly reduced at the initial follow‐up between 1 and 3 months (from 5.08 to 3.5, P &lt; 0.05) </p> <p>Mean CAS at last follow‐up was 1.58 (P &lt; 0.001)</p> <p>CAS was not initially reduced in 4 participants.</p> <p>Mean VISA severity score decreased significantly (from 12 to 6, P &lt; 0.001).</p> <p>Average quality of life score was reduced post treatment (from 45/70 to 37/70) at an average of 6 months follow‐up. </p> <p>Thyrotropin receptors were reduced in all participants post treatment but not significantly.</p> <p>8 participants were checked for B cell subsets pre‐ and post‐ treatment, and all showed depletion of CD19 post RTX treatment (0.26 X 10<sup>9</sup>/L to 0.04 X 10<sup>9</sup>/L, P &lt; 0.001) </p> <p> </p> <p>Adverse effects: </p> <p>No serious adverse events were noted.</p> <p>4 patients had minor infusion‐related rashes that resolved with 10 mg IV chlorphenamine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0067" title="VannucchiG ,  CampiI ,  CovelliD ,  CurròN ,  LazzaroniE ,  PalombaA ,  et al. Efficacy profile and safety implications of very low dose rituximab in patients with graves' orbitopathy [ ]. Thyroid 2021;31(5):821-8.">Vannucchi G 2020</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy profile and safety implications of very low dose rituximab in patients with Graves' orbitopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 people with active moderate to severe TAO (9 people were unresponsive to IVMP, 8 people were newly diagnosed with TAO).   </p> <p>14 women, 3 men</p> <p>Mean age: 51.5 (SD 11.6) years (range 28 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single RTX infusion of 100 mg over 1 hour and 15 minutes.</p> <p>Oral paracetamol (1 g), chlorphenamine (10 mg) and IV hydrocortisone (100 mg) were given 1 hour prior to RTX infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were assessed at baseline and at 4, 8, 12, 16, 24, 32, 40, and 76 weeks post treatment: </p> <p>Decrease of 2 or more points in CAS</p> <p>Prevalence and time of disease inactivation (number of patients with CAS &lt; 3)</p> <p>Composite ophthalmic score for severity at 24 weeks</p> <p>TSH receptor antibodies</p> <p>Long‐term surgical treatment</p> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean baseline CAS was 4.56 (SD 0.96), decreasing to 1.25 (SD 1.14) at 24 weeks (P = 0.001). </p> <p>13 participants (86.6%) had inactive TAO at 12 weeks (CAS &lt; 3) </p> <p>Participants with longer disease duration responded to RTX as well as those with short duration. </p> <p>After 4 weeks, the responses of the long disease duration group were overall better (P &lt; 0.0001). </p> <p>Composite ophthalmic score for severity at 24 weeks improved in 58.3% of participants.</p> <p>All participants had peripheral depletion of CD20+ and CD19+ cells at the end of RTX infusion (60 minutes). </p> <p>A decrease of TSH receptor antibodies was observed at 12 weeks (P = 0.14), and a significant decrease was observed at 24 weeks (P = 0.015). </p> <p>2 participants required orbital decompression.</p> <p> </p> <p>Adverse events:</p> <p>1 participant had urticaria which resolved with low dose steroids.</p> <p>1 participant had cytokine release syndrome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>FT4:</b> free thyroxine; <b>IV:</b> intravenous; <b>IVMP:</b> intravenous methylprednisolone; <b>QoL:</b> quality of life; <b>RTX:</b> rituximab; <b>SD:</b> standard deviation; <b>TAO:</b> thyroid‐associated ophthalmopathy; <b>TBII:</b> thyrotropin receptor binding inhibitory immunoglobulin; <b>TFTs:</b> thyroid function tests; <b>TSH:</b> thyroid‐stimulating hormone; <b>TSI:</b> thyroid‐stimulating immunoglobulin  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C. </p> </div> </div> <div class="table" id="CD009226-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Case reports</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0006" title="KrassasGE , StafilidouA , BoboridisKG . Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clinical Endocrinology2010;72(6):853-5. ">Krassas 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Case unilateral severe TAO (Grave's disease then euthyroid after treatment). TRAb high. TgAb and TPOAb normal. Previously had IV steroids for TAO. RTX 2 infusions 1 g over 4 hours 2 weeks apart. TAO got worse, developed optic neuropathy and had to have orbital decompression. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0009" title="SalviM , VannucchiG , CurròN , IntronaM , RossiS , BonaraP , et al. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Archives of Ophthalmology2012;130(1):122-4. ">Salvi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small dose of rituximab for Graves orbitopathy: new insights into the mechanism of action </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 patients treated with one‐off low dose RTX infusion 100 mg</p> <p> </p> <p>Patient 1: woman age 43 years, CAS 5/10. At day 1, CAS decreased to 1/10 and proptosis reduced from 24.5 to 23 mm in the right eye and 31 to 28 mm in the left eye. </p> <p> </p> <p>Patient 2: woman age 67 years, CAS 6/10. Vision improved within 3 hours from counting fingers to 10/10. At week 1, CAS decreased to 3 and proptosis from 27.5 to 26 mm in the right eye and 29.5 to 27 mm in the left eye. </p> <p> </p> <p>Patient 3: woman age 50 years, CAS 6/7. No immediate effects. At 8 weeks, CAS reduced to 3. </p> <p> </p> <p>No relapse at 32, 55, and 86 weeks follow up, respectively</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>RTX:</b> rituximab; <b>TAO:</b> thyroid‐associated ophthalmopathy; <b>TgAb:</b> thyroglobulin antibodies; <b>TPOAb:</b> thyroid peroxidase antibodies; <b>TRAb:</b> thyrotropin receptor autoantibodies  </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009226-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0075" title="YuJH , DaiDQ , ZhangP , LiaoHF , QinY , WangYH . Meta-analysis of the efficacy of Rituximab in thyroid associated ophthalmopathy. International Eye Science2020;20(8):1379-83.">Yu 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Meta‐analysis of the efficacy of rituximab in thyroid‐associated ophthalmopathy.</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 studies: 2 RCTs and 4 cohort studies</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meta‐analysis on RTX clinical studies in moderate to severe thyroid‐associated ophthalmopathy</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS before and after RTX treatment</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS reduced significantly (SMD ‐5.04, 95% CI ‐7.08 to ‐3.01; P &lt; 0.00001)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RTX:</b> rituximab; <b>SMD:</b> standard mean difference </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD009226-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, the risk of bias was considered low across all domains except for the bias introduced by the early termination of both studies. The allocation concealment was not clearly described in the study by <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>. See <a href="#CD009226-fig-0002">Figure 2</a> for the summary of the risk of bias assessment. </p> <div class="figure" id="CD009226-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009226-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_n/nCD009226-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009226-sec-0048"> <h4 class="title">Allocation</h4> <p>Both included studies performed block randomisation to allocate treatment (low risk). The allocation concealment was adequate (low risk) for <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> but was not clearly described in <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a>. </p> </section> <section id="CD009226-sec-0049"> <h4 class="title">Blinding</h4> <p>Both participants and ophthalmologists were masked in both studies (low risk). Regarding masking of outcome assessments, we considered the risk of bias to be low in both studies. </p> </section> <section id="CD009226-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>The attrition rate was broadly equal between the two treatment arms for both studies, and all pre‐specified outcomes were reported (low risk). </p> </section> <section id="CD009226-sec-0051"> <h4 class="title">Selective reporting</h4> <p>All pre‐specified outcomes were reported in both studies (low risk).</p> </section> <section id="CD009226-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Neither study achieved the target sample size. <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> was terminated early based on the evidence of frequent disease reactivation in the IVMP arm. Furthermore, <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> amended the rituximab infusion protocol after the first 12 participants. In <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a>, the study was concluded before reaching full enrolment due to recruitment difficulties. </p> </section> </section> <section id="CD009226-sec-0053"> <h3 class="title" id="CD009226-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD009226-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy</a>; <a href="./full#CD009226-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Rituximab compared to placebo for thyroid‐associated ophthalmopathy</a> </p> <section id="CD009226-sec-0054"> <h4 class="title">Rituximab compared to intravenous methylprednisolone</h4> <p>See: <a href="./full#CD009226-tbl-0001">summary of findings Table 1</a> and <a href="#CD009226-tbl-0007">Table 5</a> </p> <div class="table" id="CD009226-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rituximab versus intravenous methylprednisolone</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcome<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>RTX</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>IVMP</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS improvement (decrease) by 2 or more points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.98 to 1.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOSPECS<sup>b</sup> improvement (decrease) by 2 or more classes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.25 to 4.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proptosis improvement (decrease) by 2 mm or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.02 to 8.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpebral aperture improvement (decrease) by 3 mm or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.31 (0.28 to 102.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motility improvement (increase) by 1 class or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.25 to 4.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life: improvement on GO‐QoL scale by at least 6 points for "appearance"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.69 to 2.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life: improvement on GO‐QoL scale by at least 6 points for "functioning"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.25 to 1.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.90 to 2.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>CI:</b> confidence interval;<b>GO‐QoL:</b> Graves' ophthalmopathy quality of life; <b>IVMP:</b> intravenous methylprednisolone; <b>n:</b> number of events; <b>N:</b> number of participants; <b>RR:</b> risk ratio; <b>RTX:</b> rituximab    </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>All outcomes measured at 24 weeks apart from adverse events at any time period </p> <p><sup>b</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C.  </p> </div> </div> <section id="CD009226-sec-0055"> <h5 class="title">Primary outcomes</h5> <section id="CD009226-sec-0056"> <h6 class="title">CAS</h6> <p>CAS improvement (decrease) by 2 or more points was assessed at 24 weeks. <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> found that rituximab may result in an improvement in CAS compared with IVMP (RR 1.32, 95% CI 0.98 to 1.78). Using the GRADE approach, we downgraded the certainty of the evidence by two levels to low (one level for serious risk of bias as the study was stopped early, and one level for imprecision because we noted a wide confidence interval that includes no effect).  </p> </section> </section> <section id="CD009226-sec-0057"> <h5 class="title">Secondary outcomes</h5> <section id="CD009226-sec-0058"> <h6 class="title">NOSPECS</h6> <p>NOSPECS improvement (decrease) by 2 or more classes was assessed at 24 weeks. <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> showed that rituximab may have little or no effect on NOSPECS (RR 1.07, 95% CI 0.25 to 4.49). We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision because it is a small study with few events and the confidence interval is very wide, including no effect). </p> </section> <section id="CD009226-sec-0059"> <h6 class="title">Proptosis</h6> <p>Proptosis improvement (decrease) by 2 mm or more was assessed at 24 weeks. The evidence of <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> on the effect of rituximab on proptosis is inconclusive (RR 0.35, 95% CI 0.02 to 8.08). We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision because it is a small study with few events and the confidence interval is very wide, including no effect). </p> </section> <section id="CD009226-sec-0060"> <h6 class="title">Palpebral aperture</h6> <p>Palpebral aperture improvement (decrease) by 3 mm or more was assessed at 24 weeks. The evidence on the effect of rituximab on palpebral aperture in <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> is inconclusive (RR 5.31, 95% CI 0.28 to 102.38). We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision because it is a small study with few events and the confidence interval is very wide, including no effect).  </p> </section> <section id="CD009226-sec-0061"> <h6 class="title">Motility </h6> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> assessed the motility outcome as an improvement (increase) by 1 class or more at 24 weeks. The evidence on the effect of rituximab on motility measured by the Gorman scale is inconclusive (RR 1.07, 95% CI 0.25 to 4.49). We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision because it is a small study with few events and the confidence interval is very wide, including no effect). </p> </section> <section id="CD009226-sec-0062"> <h6 class="title">Quality of life </h6> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> used the GO‐QoL to assess quality of life at 24 weeks. The evidence on the effect of rituximab on quality of life is inconclusive. The risk ratio for improvement by at least 6 points was 0.58 (95% CI 0.25 to 1.32) for "functioning" and 1.39 (95% CI 0.69 to 2.82) for "appearance". We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, one level for imprecision as it is a small study with wide confidence intervals including no effect, and one level for inconsistency as effects on quality of life are inconsistent in two domains assessed). </p> </section> <section id="CD009226-sec-0063"> <h6 class="title">Adverse events</h6> <p>The risk ratio for adverse events in <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> was 1.39 with a 95% CI of 0.90 to 2.13. In the rituximab group, two participants experienced a major infusion reaction, likely cytokine release syndrome. Minor adverse effects were observed in most rituximab participants at the first infusion. In the IVMP group, three participants experienced deranged liver function tests. Minor side effects were observed in seven IVMP participants and these included dyspepsia, hypotension, insomnia, and mild mood disorders. We downgraded the certainty of the evidence by two levels to low (one level for serious risk of bias as the study was stopped early, and one level for imprecision as it is a small study and the confidence interval is wide, including no effect). </p> </section> </section> </section> <section id="CD009226-sec-0064"> <h4 class="title">Rituximab compared to placebo</h4> <p>See <a href="./full#CD009226-tbl-0002">summary of findings Table 2</a> and <a href="#CD009226-tbl-0008">Table 6</a> </p> <div class="table" id="CD009226-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Rituximab versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcome<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>RTX</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS improvement (decrease) by 2 or more points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.34 to 4.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOSPECS<sup>b</sup> improvement (decrease) by 2 or more classes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.15 to 5.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proptosis improvement (decrease) by 2 mm or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.10 to 2.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.46 (0.84 to 7.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>CI:</b> confidence interval; <b>n:</b> number of events; <b>N:</b> number of participants; <b>RR:</b> risk ratio; <b>RTX:</b> rituximab </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>All outcomes measured at 24 weeks apart from adverse events at any time period </p> <p><sup>b</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C.  </p> </div> </div> <section id="CD009226-sec-0065"> <h5 class="title">Primary outcomes</h5> <section id="CD009226-sec-0066"> <h6 class="title">CAS</h6> <p>Improvement (decrease) in CAS by 2 or more points was assessed at 24 weeks. The evidence on the effect of rituximab on CAS compared to placebo is inconclusive (RR 1.23, 95% CI 0.34 to 4.40). We downgraded the certainty of the evidence by thee levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision as it is a small study and the confidence interval is very wide, including no effect).  </p> </section> </section> <section id="CD009226-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD009226-sec-0068"> <h6 class="title">NOSPECS</h6> <p>NOSPECS improvement (decrease) by 2 or more classes was assessed at 24 weeks. <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> demonstrated that rituximab may have little to no effect on NOSPECS (RR 0.92, 95% CI 0.15 to 5.56). We downgraded the certainty of the evidence to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision as it is a small study and the confidence interval is very wide, including no effect). </p> </section> <section id="CD009226-sec-0069"> <h6 class="title">Proptosis</h6> <p>Proptosis improvement (decrease) by 2 mm or more was assessed at 24 weeks. <a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> demonstrated that rituximab may not result in improvement in proptosis (RR 0.46, 95% CI 0.10 to 2.08). We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision as it is a small study and the confidence interval is very wide, including no effect).  </p> </section> <section id="CD009226-sec-0070"> <h6 class="title">Palpebral aperture</h6> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> showed that rituximab may have little to no effect on palpebral aperture at 24 weeks. The median change in right eye palpebral aperture at 24 weeks was 0 mm (IQR ‐1 to 1) in the 13 people who received rituximab versus ‐0.5 mm (IQR ‐1 to 1.75) in the 12 people who received placebo. The median change in left eye palpebral aperture was 0 mm (IQR ‐1.5 to 1) in the rituximab group versus 0.5 mm (IQR ‐1 to 1.75) in the placebo group. We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, one level for inconsistency as there were different findings in the right and left eye, and one level for imprecision as it is a small study).  </p> </section> <section id="CD009226-sec-0071"> <h6 class="title">Motility </h6> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> produced inconclusive evidence on the effect of rituximab on motility. The median diplopia score in the rituximab group was 3 (IQR 2 to 3.5) compared with 2.5 (IQR 0 to 4) in the placebo group. We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision because it was a small study (fewer than 30 participants) ​and we were unable to calculate the effect estimate and its precision). </p> </section> <section id="CD009226-sec-0072"> <h6 class="title">Quality of life </h6> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> used SF‐12 physical and mental scores to assess quality of life at 24 weeks, producing inconclusive results. The median score for the physical component was 45.9 (IQR 43.6 to 50.8) in the 13 participants who received rituximab versus 40.3 (IQR 38.5 to 52.1) in the 12 participants who received placebo; and the median score for the mental component was 52.8 (IQR 36.1 to 56.7) in the rituximab group versus 46.1 (IQR 35.4 to 57.4) in the placebo group. We downgraded the certainty of the evidence by three levels to very low certainty (one level for serious risk of bias as the study was stopped early, and two levels for imprecision as it is a small study (fewer than 30 participants) ​and we were unable to calculate the effect estimate and its precision).  </p> </section> <section id="CD009226-sec-0073"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> demonstrated that rituximab may increase adverse effects (RR 2.46, 95% CI 0.84 to 7.18). Three and eight participants experienced adverse effects in the placebo group and the rituximab group, respectively. We downgraded the certainty of the evidence by three levels to very low (one level for serious risk of bias as the study was stopped early, and two levels for imprecision as it is a small study and the confidence interval is very wide, including no effect).  </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009226-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009226-sec-0074"></div> <section id="CD009226-sec-0075"> <h3 class="title" id="CD009226-sec-0075">Summary of main results</h3> <p>This Cochrane review summarises the key findings from two RCTs meeting the inclusion criteria to assess the efficacy of rituximab. Given the differences in comparator groups (placebo for one study and intravenous steroids for the other), a meta‐analysis was not possible. The two studies included 56 adults with active TAO. We found low‐certainty evidence that rituximab may result in an improvement in CAS compared with IVMP, and very low‐certainty evidence that rituximab may improve or have little to no effect on CAS when compared with placebo. The certainty of evidence was downgraded due to the early termination of the study, the small number of participants and the wide confidence intervals. There was either low‐ or very low‐certainty evidence that rituximab has any effect on secondary outcomes including NOSPECS, proptosis, palpebral aperture, motility and quality of life when compared to either IVMP or placebo. There was low‐certainty and very low‐certainty evidence that rituximab may increase the adverse effects compared to IVMP and placebo, respectively.  </p> <p>The first authors of the two RCTs of RTX in TAO conducted a post‐hoc analysis of their studies (<a href="./references#CD009226-bbs2-0063" title="StanMN , SalviM . Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials. European Journal of Endocrinology2017;176(2):R101-9.">Stan 2017</a>). They concluded that the study participant characteristics differed between the two studies, as the people included in the Italian study were younger, with lower TRAb and shorter disease (favourable factors for better response), although more of them were smokers (associated with poorer response). A severity outcome was reassessed by calculating a composite ophthalmic score proposed by EUGOGO (<a href="./references#CD009226-bbs2-0017" title="BartalenaL , KrassasGE , WiersingaW , MarcocciC , SalviM , DaumerieC , et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2012;97(12):4454-63.">Bartalena 2012</a>) to quantify the change of severity of the disease after therapy. There was an improvement in disease severity in 60% of participants after RTX compared to 37.5% after steroids (<a href="./references#CD009226-bbs2-0063" title="StanMN , SalviM . Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials. European Journal of Endocrinology2017;176(2):R101-9.">Stan 2017</a>). In addition, the post‐hoc data demonstrated that the long‐term disease relapse rate following treatment with RTX was low. They concluded that RTX might be considered as a second‐line treatment in people with early active moderate to severe TAO that is unresponsive to the initial therapy. </p> <p>There is one ongoing study that is likely to meet inclusion criteria once published. <a href="./references#CD009226-bbs2-0012" title="EUCTR2011-000899-33-SE. Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2011-000899-33-SE+  accessed 3 March 2022. ">EUCTR2011‐000899‐33‐SE</a> is a phase 2/3 randomised open trial of rituximab+methotrexate versus oral steroids+methotrexate in 50 people with moderate to severe TAO (CAS ≥ 4) who have relapsed six weeks after responding to a 12‐week course of weekly intravenous steroid infusions. Participants must have been euthyroid for at least six weeks prior to starting treatment with intravenous steroids. The primary outcome measure is improvement in CAS by 2 or more points. However, this study is unlikely to be directly comparable to the two published RCTs due to concomitant methotrexate therapy in the trial protocol. </p> </section> <section id="CD009226-sec-0076"> <h3 class="title" id="CD009226-sec-0076">Overall completeness and applicability of evidence</h3> <p>Evidence was limited to two studies with few participants. No meta‐analysis was possible as there was only one study comparing rituximab with IVMP and another with placebo.  </p> <p>The study populations were different in the two studies. The study by <a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> enrolled younger, predominantly female patients with shorter disease duration and lower pre‐treatment TRAb levels, which could have influenced the treatment response.  </p> </section> <section id="CD009226-sec-0077"> <h3 class="title" id="CD009226-sec-0077">Quality of the evidence</h3> <p>We used the GRADE approach to assess the quality of evidence for this review. The evidence was either low or very low certainty for all outcomes measured for both comparisons. Reasons for downgrading the certainty of the evidence were the early termination of both studies, which increases risk of bias; the small participant numbers and wide confidence intervals including no effect, which increase imprecision; and the inconsistency of reported results for the right and left eyes.  </p> </section> <section id="CD009226-sec-0078"> <h3 class="title" id="CD009226-sec-0078">Potential biases in the review process</h3> <p>We conducted a thorough search and two review authors assessed study eligibility and risk of bias of the included studies to minimise potential biases in the review process.  </p> </section> <section id="CD009226-sec-0079"> <h3 class="title" id="CD009226-sec-0079">Agreements and disagreements with other studies or reviews</h3> <p>We found no systematic reviews that investigated the efficacy of rituximab in TAO in RCTs. <a href="./references#CD009226-bbs2-0049" title="OstrowskiRA , BusseyMR , ShayestehY , JayWM . Rituximab in the treatment of thyroid eye disease: a review. Neuroophthalmology  2015;39(3):109-15.">Ostrowski 2015</a> found variable results with regard to the value of rituximab as a treatment for TAO. <a href="./references#CD009226-bbs2-0071" title="WangC , NingQ , JinK , XieJ , YeJ . Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmology2018;18:46. [DOI: https://doi.org/10.1186/s12886-018-0679-4]">Wang 2018</a> conducted a systematic review and included 11 studies, finding a decline in CAS at 1, 3, 6, and 12 months after rituximab treatment. However, the authors noted that a large, high‐quality study is required.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009226-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/urn:x-wiley:14651858:media:CD009226:CD009226-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD009226-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_n/nCD009226-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_t/tCD009226-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_n/nCD009226-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009226-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/urn:x-wiley:14651858:media:CD009226:CD009226-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009226-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_n/nCD009226-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_t/tCD009226-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/media/CDSR/CD009226/image_n/nCD009226-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009226-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> thyroid‐associated ophthalmopathy<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> rituximab<br/><b>Comparison:</b> intravenous methylprednisolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravenous methylprednisolone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rituximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAS improvement (decrease) by 2 or more points<br/>follow‐up: 24 weeks<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>990 per 1000</b><br/>(735 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b><br/>(0.98 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NOSPECS improvement (decrease) by 2 or more classes<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(47 to 842) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.25 to 4.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proptosis improvement (decrease) by 2 mm or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(1 to 505) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.35</b><br/>(0.02 to 8.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Palpebral aperture improvement (decrease) by 3 mm or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.31</b><br/>(0.28 to 102.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><br/>(3 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motility improvement (increase) by 1 class or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(47 to 842) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.25 to 4.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life improvement by at least 6 points<br/>assessed with: GO‐QoL<br/>follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Improvement on GO‐QoL Scale by at least 6 points for "functioning": RR at 24 weeks 0.58 (95% CI 0.25 to 1.32)Improvement on GO‐QoL Scale by at least 6 points for "appearance": RR at 24 weeks 1.39 (95% CI 0.69 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>869 per 1000</b><br/>(563 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.39</b><br/>(0.90 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the rituximab group, 2 participants experienced a major infusion reaction, likely cytokine release syndrome. Minor adverse effects (mild infusion reactions) were observed in most rituximab patients at first infusion. In IVMP group, 3 participants experienced deranged liver function test. Minor side effects observed in 7 IVMP participants were dyspepsia, hypotension, insomnia, and mild mood disorders, which did not require specific treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424436778554984307" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424436778554984307</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> CAS: clinical activity score; GO‐QoL: Graves’ ophthalmopathy quality of life questionnaire; NOSPECS: scoring system based on no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement, and sight loss; RCT: randomised clinical trial; SF‐12: Medical Outcomes Study 12‐Item Short Form Health Survey.<br/><sup>b</sup> Downgraded one level for serious risk of bias: study was stopped early. <br/><sup>c</sup> Downgraded one level for imprecision: small study, wide confidence intervals including no effect<br/><sup>d</sup> Downgraded two levels for imprecision: small study with few events, very wide confidence intervals<br/><sup>e</sup> Downgraded one level for inconsistency: effects on quality of life are inconsistent </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009226-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Rituximab compared to placebo for thyroid‐associated ophthalmopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rituximab compared to placebo for thyroid‐associated ophthalmopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> thyroid‐associated ophthalmopathy<br/><b>Setting:</b> Hospital<br/><b>Intervention:</b> Rituximab<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Rituximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAS improvement (decrease) by 2 or more points<br/>follow‐up: 24 weeks<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/>(85 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b><br/>(0.34 to 4.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NOSPECS improvement (decrease) by 2 classes or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b><br/>(25 to 927) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.15 to 5.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proptosis improvement (decrease) by 2 mm or more<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b><br/>(33 to 693) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b><br/>(0.10 to 2.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpebral aperture change<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median change in palpebral aperture in the right eye was 0 mm (IQR ‐1 to 1) in the 13 rituximab group participants and ‐0.5 mm (IQR ‐1 to 1.75) in the 12 placebo participants. Median change in the palpebral aperture in the left eye was 0 mm (IQR ‐1.5 to 1) in the rituximab group and 0.5 mm (IQR ‐1 to 1.75) in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motility<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The median diplopia score in the 13 rituximab participants was 3 (IQR 2 to 3.5) compared to 2.5 (IQR 0 to 4) in the 12 placebo participants. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life<br/>assessed with: SF‐12 physical and mental<br/>follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>SF‐12 physical: the median score was 45.9 (IQR 43.6 to 50.8) in the 13 rituximab participants and 40.3 (IQR 38.5 to 52.1) in the 12 placebo participants. SF‐12 mental: the median score was 52.8 (IQR 36.1 to 56.7) in the rituximab group and 46.1 (IQR 35.4 to 57.4) in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>615 per 1000</b><br/>(210 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.46</b><br/>(0.84 to 7.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were four adverse events in 3 out of 12 placebo patients (1 moderate/severe) and 11 adverse events in 8 out of 13 rituximab‐treated patients (5 moderate/severe). Moderate/severe adverse effects included infections (bronchitis, conjunctivitis), vasculitis, optic neuropathy and gastrointestinal adverse effects including tongue pain, abdominal pain and diarrhoea. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424437036185390139" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424437036185390139</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> CAS: clinical activity score; IQR: interquartile range; GO‐QoL: Graves’ ophthalmopathy quality of life questionnaire; NOSPECS: scoring system based on no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement, and sight loss; RCT: randomised clinical trial; SF‐12: Medical Outcomes Study 12‐Item Short Form Health Survey.<br/><sup>b</sup> Downgraded one level for serious risk of bias: study was stopped early<br/><sup>c</sup> Downgraded two levels for imprecision: small study and (where confidence intervals could be calculated) very wide confidence intervals including no effect<br/><sup>d</sup> Downgraded one level for inconsistency: different findings in right and left eye </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Rituximab compared to placebo for thyroid‐associated ophthalmopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009226-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Non‐randomised controlled trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009226-bbs2-0003" title="El FassiD , NielsenCH , BonnemaSJ , HasselbachHC , HegedüsL . B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. Journal of Clinical Endocrinology and Metabolism2007;92(5):1769-72. El FassiD , NielsenCH , HasselbalchHC , HegedüsL . Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid2006;16(7):709-10. El FassiD , NielsenCH , KjeldsenJ , ClemmensenO , HegedüsL . Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut2008;57(5):714-5. ">El Fassi 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with newly diagnosed or relapsed untreated Grave's disease<br/>  </p> <p>RTX group: 10 participants.</p> <p>Control group: 10 participants</p> <p>18 women, 2 men</p> <p>Age range: 18 to 65 years</p> <p>No participants had received immunosuppressants.</p> <p>Consecutive eligible people offered RTX and control participants were those who declined</p> <p> </p> <p>Only 2 participants in RTX group and no participants in control group had active TAO:</p> <p>Participant 1: woman, aged 64, ex‐smoker; CAS 6</p> <p>Participant 2: woman, aged 35, ex‐smoker; CAS 4/5 (right/left)</p> <p> </p> <p>Follow‐up:</p> <p>RTX group: 740 (435 to 904) days</p> <p>Control group: 554 (99 to 741) days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants rendered euthyroid with methimazole for 4 months</p> <p>RTX group: RTX IV infusion 375 mg per m<sup>2</sup> body surface area on day 1, 8, 15 and 22 </p> <p>Pretreatment with 1 g oral acetaminophen, 2 mg IV clemastine</p> <p>Control group: no further treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to relapse of hyperthyroidism</p> <p>Changes in autoantibody level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 patients in RTX group remained in remission with median follow‐up 705 days</p> <p>All participants in control group relapsed by 393 days (P &lt; 0.05)</p> <p>All participants in remission had initial TRAb levels below 5 IU/litre</p> <p>None of 5 participants in control group with corresponding low TRAb levels stayed in remission (P &lt; 0.01) </p> <p> </p> <p>2 participants in RTX group with active TAO:</p> <p>Participant 1: CAS reduced from 6 to 2 in 8 months; proptosis reduced from 25 mm to 22 mm bilaterally. </p> <p>Participant 2: CAS 4/5 (right/left) reduced to 2/3 at 5 weeks, 2/4 at 5 months and 1/1 at 11 months; proptosis changed from 23 mm bilaterally to 21 mm/23 mm (right/left). </p> <p>Both participants improved in soft tissue changes and eye motility.</p> <p> </p> <p>Adverse effects:</p> <p>After first infusion only: hypotension (n = 4), nausea (n = 2), fever (n = 1), chills (n = 1), and tachycardia (n = 1) </p> <p>2 participants had slight pain in the finger joints</p> <p>1 participant developed ulcerative colitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009226-bbs2-0008" title="BonaraP , VannucchiG , CampiI , RossiS , CantoniF , FrugoniC , et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clinical Reviews in Allergy and Immunology2008;34(1):118-23. SalviM , VannucchiG , CampiI , CurròN , DazziD , SimonettaS , et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology2007;156(1):33-40. SalviM , VannucchiG , CampiI , CurròN , SimonettaS , CoveliD , et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clinical Immunology2009;131(2):360-5. SalviM , VannucchiG , CampiI , RossiS , BonaraP , SbrozziF , et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology2006;154(4):511-7. ">Salvi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment of Graves’ disease and associated ophthalmopathy with the anti‐CD20 monoclonal antibody rituximab: an open study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with Grave's disease and TAO<br/>  </p> <p>RTX group: 9 participants</p> <p>7 women, 2 men</p> <p>Age range: 31 to 51 years.</p> <p>5 smokers, 2 ex‐smokers, 2 non‐smokers</p> <p>2 participants mild signs; 6 moderate; 1 severe<br/>  </p> <p>Steroid group: 20 participants</p> <p>17 women, 3 men</p> <p>Age range: 30 to 82 years</p> <p>12 smokers, 4 ex‐smokers, 4 non‐smokers</p> <p>3 participants mild TAO, 13 moderate, 4 severe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTX group: RTX IV infusion 1000 mg over 4 hours 15 minutes, twice with a 2‐week interval. 1 g oral paracetamol and 10 mg oral chlorpheniramine administered prior to RTX treatment. </p> <p>Steroid group: methylprednisolone 500 mg IV once a week for 14 weeks then 250 mg once a week for further 2 weeks </p> <p> </p> <p>Follow‐up:</p> <p>RTX group: 1 participant 5 months, 8 participants 12 months or more</p> <p>Steroid group: 12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in CAS</p> <p>Change in NOSPECS<sup>a</sup> score </p> <p>Thyroid function</p> <p>Lymphocyte count</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTX group:</p> <p>All participants had peripheral B‐cell depletion with first infusion. Depletion lasted 4 months in 3 participants, 5 months in 5 participants, and 1 still depleted at 5 months. </p> <p>Thyroid function not affected</p> <p>Change in TgAb, TPOAb and TRAb not significant and not correlated to CD20+ lymphocyte depletion </p> <p>Mean CAS before 4.7 (SD 0.5), reduced to 1.8 (SD 0.8) at 30 weeks (P &lt; 0.0001)</p> <p>Proptosis (NOSPECS<sup>a</sup> class 3) reduced significantly in participants with active TAO, from 22.4 (SD0.5) to 20.9 (SD0.6) (P &lt; 0.0001) and in Graves' disease with lid signs, from 19.0 (SD 0.7) to 17.3 (SD0.9) (P &lt; 0.003) at 30 weeks </p> <p>Soft tissue inflammation (NOSEPCS<sup>a</sup> 2) decreased significantly (P &lt; 0.001) </p> <p>Degree of motility impairment (NOSPECS<sup>a</sup> 4) reduced (P &lt; 0.05) </p> <p>No relapse at time of B cell return and in subsequent 5 to 7 months of follow up</p> <p>One participant clinically responsive to RTX (no change in TRAb) later had thyroidectomy and orbital decompression. B cells found in thyroid tissue but none in orbital tissue. </p> <p> </p> <p>Steroid group:</p> <p>Mean serum TRAb 16.3 (SD 4.9) U/L before and 9.3 (SD 3.6) U/L after (non‐significant). No difference compared to RTX at 30 weeks. </p> <p>Mean CAS 4.1 (SD 0.03) before and 2.0 (SD0.4) at 30 weeks (P &lt; 0.0001)</p> <p>Significantly more change in CAS with RTX than with IVGC (P &lt; 0.05)</p> <p>Mean proptosis reduced from 22.6 (SD 0.6) to 22.1 (SD 0.6) at 30 weeks (P &lt; 0.014). No significant difference compared to RTX. </p> <p>Soft tissue inflammation decreased significantly at 30 weeks (P &lt; 0.003) but no significant difference compared to RTX </p> <p>4 participants did not respond to IVGC and one underwent acute orbital decompression for optic neuropathy </p> <p>2 participants also had relapse of TAO 6 to 8 weeks after IVGC withdrawal</p> <p> </p> <p>Adverse effects:</p> <p>RTX: minor side effects in 3 participants with first infusion (nose and throat itching, mild temperature elevation) </p> <p>Steroids: adverse effects more frequent (9 participants) and of greater clinical significance (flushing, insomnia, dyspepsia, hyperglycaemia, serum aminotransferases or GGT increase) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>GGT:</b> gamma‐glutamyl transferase; <b>IV:</b> intravenous; <b>IVGC:</b> intravenous glucocorticoids; <b>RTX:</b> rituximab; <b>SD:</b> standard deviation; <b>TAO:</b> thyroid‐associated ophthalmopathy; <b>TgAb:</b> thyroglobulin antibodies; <b>TPOAb:</b> thyroid peroxidase antibodies; <b>TRAb:</b> thyrotropin receptor autoantibodies </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Non‐randomised controlled trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009226-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Non‐randomised case series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0004" title="HeemstraKA , ToesRE , SepersJ , PereiraAM , CorssmitEP , HuizingaTW , et al. Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology2008;159(5):609-15. ">Heemstra 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab in relapsing Graves’ disease, a phase II study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 people with relapsing Graves' disease</p> <p>9 women, 4 men</p> <p>Mean age: 39.5 (SD 9.5) years</p> <p>Previously adequately treated with at least 1 year antithyroid medications</p> <p>Median CAS was 0 (range 0 to 2)</p> <p>3 participants had NOSPECS<sup>a</sup> 2a3040 </p> <p> </p> <p>Follow up: 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX IV infusion 1000 mg, twice with a 2‐week interval.</p> <p>Pre‐medication 10 mg IV dexamethasone plus 2 mg IV clemastine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absence of hyperthyroidism</p> <p>Relapse free survival time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants had decrease in C19 and MS4A1 (lymphocyte populations)</p> <p>4 participants no response</p> <p>Other 9 participants: FT4 decreased at 16 weeks (P = 0.001) and TSH increased (P = 0.011) </p> <p>At follow‐up 14 to 27 months, 9 participants still euthyroid with normal FT4 (P &lt; 0.001) and TSH (P = 0.008) </p> <p> </p> <p>Adverse effects: 2 participants had temporary joint pains</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0005" title="KhannaD , ChongKK , AfifiyanNF , HwangCJ , LeeDK , GarneauHC , et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology2010;117(1):133-9. ">Khanna 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab treatment of patients with severe, corticosteroid‐resistant thyroid‐associated ophthalmopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 people with severe progressive TAO unresponsive to steroids</p> <p>4 women, 2 men</p> <p>Mean age: 54.3 (SD 9.1) years</p> <p>3 current smokers</p> <p> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX IV infusion 1000 mg, twice with a 2‐week interval</p> <p>Pre‐medication 100 mg IVMP, 1 g oral acetaminophen plus 50 mg oral diphenhydramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in CAS</p> <p>Change in proptosis</p> <p>Change in strabismus</p> <p>Side effects</p> <p>Quantification of regulatory T cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean CAS improved from 5.5 (SD 0.8) to 1.3 (SD 0.5 )at 2 months after treatment (P &lt; 0.03) </p> <p>CAS remained quiescent in all participants (0.7 (SD 0.8); P &lt; 0.0001) at mean follow‐up of 6.2 (SD 4.5) months </p> <p>Vision improved bilaterally in all 4 participants with dysthyroid optic neuropathy (DON) </p> <p>None of the 6 participants experienced disease relapse after RTX infusion</p> <p>Mean proptosis by Hertel measurement remained stable (24 (SD 3.7) mm before therapy and 23.6 (SD 3.7) mm after therapy (P = 0.17)) </p> <p>1 participant experienced progressive strabismus after RTX treatment</p> <p>No participants had improvement in extraocular motility</p> <p>The abundance of T regulatory cells, assessed in 1 participant who had orbital decompression 12 days after RTX, increased within 1 week of RTX and remained elevated at 18 months of follow‐up </p> <p> </p> <p>Adverse effects: urinary tract infection, hypertension. 1 participant had cardiac arrest and died 3 months after treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0010" title="SilkissRZ , ReierA , ColemanM , LauerSA . Rituximab for thyroid eye disease. Ophthalmic Plastic and Reconstructive Surgery2010;26(5):310-4. ">Silkiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rituximab for thyroid eye disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 people with active TAO (CAS of ≥ 4)</p> <p>7 women, 5 men</p> <p>Age range: 34 to 80 years</p> <p>4 smokers</p> <p>4 participants had never previously been treated with steroids</p> <p> </p> <p>Follow‐up: 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX IV infusion 1000 mg, twice with a 2‐week interval</p> <p>Pre‐medication 1 g oral acetaminophen plus 50 mg oral diphenhydramine</p> <p>Note: 2 participants were still on oral glucocorticoids during the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in CAS</p> <p>Change in thyroid‐associated ophthalmopathy scale (TAOS)</p> <p>Pre‐infusion CD20+ lymphocyte count</p> <p>Post‐infusion CD19+ lymphocyte count</p> <p>Thyroid stimulating hormone and thyroid stimulating immunoglobulin levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean CAS improved from 5.5 (SD 1.2) to 0.8 (SD 1.4) at 52 weeks after treatment (P &lt; 0.001) </p> <p>Mean TAOS improved from 10.4 (SD 5.7) to 2.4 (SD 4.6) at 52 weeks (P &lt; 0.001)</p> <p>No change in TSH or TSI levels before and after treatment</p> <p> </p> <p>Adverse effects: none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0007" title="MitchellA , GanE , MorrisM , JohnsonK , NeohC , DickinsonA , et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves’ orbitopathy. Cinical Endocrinology 2013, Jan 16;79(3):437-42. ">Mitchell 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The effect of B cell depletion therapy on anti‐TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves’ orbitopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 people with steroid‐refractory TAO</p> <p>8 women, 1 man</p> <p>Median age: 62 years (range 37 to 87)</p> <p>All participants had pulsed IVMP for a median of 3 months prior to RTX treatment (range 2 weeks to 6 months) </p> <p>8/9 participants had CAS greater than 4/10 (median 6.5, range 4 to 8). 1 participant had CAS 1. </p> <p>4 participants had sight‐threatening TAO (NOSPECS<sup>a</sup> 6) </p> <p> </p> <p>Follow‐up: 16 months or more (median 29 months, range 16 to 46 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTX infusion 1000 mg, twice with a 2‐week interval (3 participants), or 500 mg, twice with a 2‐week interval (6 participants) </p> <p>One participant not B cell depleted after second 500 mg infusion so received third 500 mg infusion </p> <p>Premedication 500 mg IVMP, 10 mg IV chlorpheniramine and 1 g oral paracetamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thyroid function tests</p> <p>B cell count</p> <p>Thyroid autoantibody levels</p> <p>Change in CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect on TFTs</p> <p>TBII reduced in all participants</p> <p>CAS improved in all participants</p> <p>Median improvement in CAS at 3 months: 2 points (range 1 to 6), P = 0.018</p> <p>Median improvement in CAS at 12 months: 5 points (range 1 to 8), P = 0.0006</p> <p> </p> <p>Adverse effects: 4 participants had minor side effects following first infusion: 2 headache, 1 headache and chills without pyrexia, 1 mild myalgia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0023" title="Deltour J-B, d’Assigny FlamenM , LadsousM , GiovansiliL , CariouB , CaronP , et al. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study. Graefes Archives for Clinical and Experimental Ophthalmology2020;258(9):2013-21.">Deltour 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 people with moderate to severe TAO who are corticosteroid resistant or corticosteroid dependent </p> <p>21 women, 11 men</p> <p>Mean age: 51.2 (SD 10.7) years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants received 2 IV injections of 1 g of RTX 2 weeks apart, with oral paracetamol (1 g), oral antihistamine treatment, and IV glucocorticoid (1 mg/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in at least 1 of the 3 dysfunctional parameters (inflammatory, oculomotor, and visual) without deterioration of the other(s) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of participants presenting signs of inflammatory activity (CAS ≥ 3) significantly diminished (74% before treatment, 45% at 12 weeks (P &lt; 0.05), 29% at 24 weeks (P &lt; 0.001)). </p> <p>The proportion of participants with visual dysfunction significantly diminished (39% before treatment, 19% at 12 weeks, then 16% at 24 weeks (P &lt; 0.05)). </p> <p>1 case had improvement in oculomotor dysfunction.</p> <p>Mean CAS significantly decreased after treatment, from 3.29 (SD 1.16) at week 0 to 1.59 (SD 1.12) at week 24 (P &lt; 0.001). </p> <p> </p> <p>Adverse effect: 1 participant had a cytokine release syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0025" title="Pasquier-Fediaevsky L,  AndreiS ,  Berche M,  Leenhardt L ,  Héron E,  Rivière S. Slow-dose rituximab for active moderate to severe graves' orbitopathy resistant to conventional treatment. Ocular Immunology and Inflammation2019;27(5):844-50.">Du Pasquier‐Fediaevsky 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose rituximab for active moderate to severe graves' orbitopathy resistant to conventional treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 people with active moderate to severe TAO who were resistant to conventional treatment (IVMP, oral corticosteroids and orbital radiotherapy). </p> <p>11 women, 4 men</p> <p>Age: 46 years (range 29 to 58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose RTX infusions (100 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS decreased by 2 points or &lt; 4/10, at 3 to 4 months after the first infusion of RTX </p> <p>Proptosis</p> <p>Lid fissure width</p> <p>Eye motility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 participants received 100 mg RTX doses (cumulative dose 100 to 400 mg)</p> <p>Mean CAS decreased from 4.6 (SD 0.89) to 2.0 (SD 1.65) at 17.1 weeks, after a mean of 2.3 infusions (range 1 to 4) of 100 mg RTX. </p> <p>Mean CAS was 1.3 (SD 1.76) at last visit at 63.6 weeks (range 44.3 to 87.5).</p> <p>RTX was effective in 13 participants, within 2 months of treatment initiation.</p> <p>In all responders except 1, TAO remained inactive after 1 year of follow‐up.</p> <p>RTX was ineffective in 2 participants, according to unchanged CAS after 2 infusions.</p> <p>All participants were euthyroid at the time of RTX treatment.</p> <p>Mean duration between the end of IVMP and RTX treatments was 16 months.</p> <p>Mean duration between the end of orbital radiotherapy and RTX treatments was 15 months.</p> <p>RTX was not clinically significant on proptosis, lid fissure width, and eye motility.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0036" title="Insull E,  Sipkova Z,  DavidJ , TurnerH , NorrisJ . Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment [ ]. Clinical Endocrinology2019;91(1):179-86.">Insull 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 people with active TAO (VISA (vision, inflammation, strabismus, appearance) CAS ≥ 3)   </p> <p>8 women, 4 men</p> <p>Age: 49 years (range 24 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐dose RTX infusion (100 mg).</p> <p>If clinically indicated, further doses of 500 mg IVMP were administered weekly.</p> <p>Depending on disease activity and severity, a steroid‐sparing agent was started (1st line methotrexate, 2nd line cyclosporin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> <p>VISA overall severity score</p> <p>OX‐TED (Oxford‐Thyroid Eye Disease) QoL scores</p> <p>TSH receptor antibodies</p> <p>B cell subsets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean CAS was significantly reduced at the initial follow‐up between 1 and 3 months (from 5.08 to 3.5, P &lt; 0.05) </p> <p>Mean CAS at last follow‐up was 1.58 (P &lt; 0.001)</p> <p>CAS was not initially reduced in 4 participants.</p> <p>Mean VISA severity score decreased significantly (from 12 to 6, P &lt; 0.001).</p> <p>Average quality of life score was reduced post treatment (from 45/70 to 37/70) at an average of 6 months follow‐up. </p> <p>Thyrotropin receptors were reduced in all participants post treatment but not significantly.</p> <p>8 participants were checked for B cell subsets pre‐ and post‐ treatment, and all showed depletion of CD19 post RTX treatment (0.26 X 10<sup>9</sup>/L to 0.04 X 10<sup>9</sup>/L, P &lt; 0.001) </p> <p> </p> <p>Adverse effects: </p> <p>No serious adverse events were noted.</p> <p>4 patients had minor infusion‐related rashes that resolved with 10 mg IV chlorphenamine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0067" title="VannucchiG ,  CampiI ,  CovelliD ,  CurròN ,  LazzaroniE ,  PalombaA ,  et al. Efficacy profile and safety implications of very low dose rituximab in patients with graves' orbitopathy [ ]. Thyroid 2021;31(5):821-8.">Vannucchi G 2020</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy profile and safety implications of very low dose rituximab in patients with Graves' orbitopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 people with active moderate to severe TAO (9 people were unresponsive to IVMP, 8 people were newly diagnosed with TAO).   </p> <p>14 women, 3 men</p> <p>Mean age: 51.5 (SD 11.6) years (range 28 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single RTX infusion of 100 mg over 1 hour and 15 minutes.</p> <p>Oral paracetamol (1 g), chlorphenamine (10 mg) and IV hydrocortisone (100 mg) were given 1 hour prior to RTX infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were assessed at baseline and at 4, 8, 12, 16, 24, 32, 40, and 76 weeks post treatment: </p> <p>Decrease of 2 or more points in CAS</p> <p>Prevalence and time of disease inactivation (number of patients with CAS &lt; 3)</p> <p>Composite ophthalmic score for severity at 24 weeks</p> <p>TSH receptor antibodies</p> <p>Long‐term surgical treatment</p> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean baseline CAS was 4.56 (SD 0.96), decreasing to 1.25 (SD 1.14) at 24 weeks (P = 0.001). </p> <p>13 participants (86.6%) had inactive TAO at 12 weeks (CAS &lt; 3) </p> <p>Participants with longer disease duration responded to RTX as well as those with short duration. </p> <p>After 4 weeks, the responses of the long disease duration group were overall better (P &lt; 0.0001). </p> <p>Composite ophthalmic score for severity at 24 weeks improved in 58.3% of participants.</p> <p>All participants had peripheral depletion of CD20+ and CD19+ cells at the end of RTX infusion (60 minutes). </p> <p>A decrease of TSH receptor antibodies was observed at 12 weeks (P = 0.14), and a significant decrease was observed at 24 weeks (P = 0.015). </p> <p>2 participants required orbital decompression.</p> <p> </p> <p>Adverse events:</p> <p>1 participant had urticaria which resolved with low dose steroids.</p> <p>1 participant had cytokine release syndrome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>FT4:</b> free thyroxine; <b>IV:</b> intravenous; <b>IVMP:</b> intravenous methylprednisolone; <b>QoL:</b> quality of life; <b>RTX:</b> rituximab; <b>SD:</b> standard deviation; <b>TAO:</b> thyroid‐associated ophthalmopathy; <b>TBII:</b> thyrotropin receptor binding inhibitory immunoglobulin; <b>TFTs:</b> thyroid function tests; <b>TSH:</b> thyroid‐stimulating hormone; <b>TSI:</b> thyroid‐stimulating immunoglobulin  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Non‐randomised case series</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009226-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Case reports</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0006" title="KrassasGE , StafilidouA , BoboridisKG . Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clinical Endocrinology2010;72(6):853-5. ">Krassas 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Case unilateral severe TAO (Grave's disease then euthyroid after treatment). TRAb high. TgAb and TPOAb normal. Previously had IV steroids for TAO. RTX 2 infusions 1 g over 4 hours 2 weeks apart. TAO got worse, developed optic neuropathy and had to have orbital decompression. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0009" title="SalviM , VannucchiG , CurròN , IntronaM , RossiS , BonaraP , et al. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Archives of Ophthalmology2012;130(1):122-4. ">Salvi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small dose of rituximab for Graves orbitopathy: new insights into the mechanism of action </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 patients treated with one‐off low dose RTX infusion 100 mg</p> <p> </p> <p>Patient 1: woman age 43 years, CAS 5/10. At day 1, CAS decreased to 1/10 and proptosis reduced from 24.5 to 23 mm in the right eye and 31 to 28 mm in the left eye. </p> <p> </p> <p>Patient 2: woman age 67 years, CAS 6/10. Vision improved within 3 hours from counting fingers to 10/10. At week 1, CAS decreased to 3 and proptosis from 27.5 to 26 mm in the right eye and 29.5 to 27 mm in the left eye. </p> <p> </p> <p>Patient 3: woman age 50 years, CAS 6/7. No immediate effects. At 8 weeks, CAS reduced to 3. </p> <p> </p> <p>No relapse at 32, 55, and 86 weeks follow up, respectively</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>RTX:</b> rituximab; <b>TAO:</b> thyroid‐associated ophthalmopathy; <b>TgAb:</b> thyroglobulin antibodies; <b>TPOAb:</b> thyroid peroxidase antibodies; <b>TRAb:</b> thyrotropin receptor autoantibodies  </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Case reports</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009226-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0075" title="YuJH , DaiDQ , ZhangP , LiaoHF , QinY , WangYH . Meta-analysis of the efficacy of Rituximab in thyroid associated ophthalmopathy. International Eye Science2020;20(8):1379-83.">Yu 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Meta‐analysis of the efficacy of rituximab in thyroid‐associated ophthalmopathy.</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 studies: 2 RCTs and 4 cohort studies</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meta‐analysis on RTX clinical studies in moderate to severe thyroid‐associated ophthalmopathy</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS before and after RTX treatment</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS reduced significantly (SMD ‐5.04, 95% CI ‐7.08 to ‐3.01; P &lt; 0.00001)</p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RTX:</b> rituximab; <b>SMD:</b> standard mean difference </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009226-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rituximab versus intravenous methylprednisolone</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcome<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>RTX</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>IVMP</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS improvement (decrease) by 2 or more points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.98 to 1.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOSPECS<sup>b</sup> improvement (decrease) by 2 or more classes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.25 to 4.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proptosis improvement (decrease) by 2 mm or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.02 to 8.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpebral aperture improvement (decrease) by 3 mm or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.31 (0.28 to 102.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motility improvement (increase) by 1 class or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.25 to 4.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life: improvement on GO‐QoL scale by at least 6 points for "appearance"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.69 to 2.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life: improvement on GO‐QoL scale by at least 6 points for "functioning"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.25 to 1.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0001" title="SalviM , VannucchiG , CurròN , CampiI , CovelliD , DazziD , et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism  2015;100(2):422-31. ">Salvi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.90 to 2.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>CI:</b> confidence interval;<b>GO‐QoL:</b> Graves' ophthalmopathy quality of life; <b>IVMP:</b> intravenous methylprednisolone; <b>n:</b> number of events; <b>N:</b> number of participants; <b>RR:</b> risk ratio; <b>RTX:</b> rituximab    </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>All outcomes measured at 24 weeks apart from adverse events at any time period </p> <p><sup>b</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rituximab versus intravenous methylprednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009226-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Rituximab versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcome<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>RTX</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS improvement (decrease) by 2 or more points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.34 to 4.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOSPECS<sup>b</sup> improvement (decrease) by 2 or more classes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.15 to 5.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proptosis improvement (decrease) by 2 mm or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.10 to 2.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009226-bbs2-0002" title="StanMN , GarrityJA , Carranza LeonBG , PrabinT , BradleyEA , BahnRS . Randomized controlled trial of rituximab in patients with Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2015;100(2):432-41. ">Stan 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.46 (0.84 to 7.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CAS:</b> clinical activity score; <b>CI:</b> confidence interval; <b>n:</b> number of events; <b>N:</b> number of participants; <b>RR:</b> risk ratio; <b>RTX:</b> rituximab </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>All outcomes measured at 24 weeks apart from adverse events at any time period </p> <p><sup>b</sup>The NOSPECS score is a scoring system based on: no symptoms or signs, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement and sight loss, graded as O, A, B or C.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Rituximab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009226.pub3/full#CD009226-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009226.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009226-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009226-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009226-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009226-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009226-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009226-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009226\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009226\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009226\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009226\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009226\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009226.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009226.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009226.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009226.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009226.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726731775"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009226.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726731779"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009226.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9ad34bda9368',t:'MTc0MDcyNjczMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 